[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2013189521A1 - Method of generating cells of hepatocyte phenotype - Google Patents

Method of generating cells of hepatocyte phenotype Download PDF

Info

Publication number
WO2013189521A1
WO2013189521A1 PCT/EP2012/061679 EP2012061679W WO2013189521A1 WO 2013189521 A1 WO2013189521 A1 WO 2013189521A1 EP 2012061679 W EP2012061679 W EP 2012061679W WO 2013189521 A1 WO2013189521 A1 WO 2013189521A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell
hepatic
ussc
hnf
Prior art date
Application number
PCT/EP2012/061679
Other languages
French (fr)
Inventor
Simon WACLAWCZYK
Anja BUCHHEISER
Georg POHLAND
Original Assignee
Waclawczyk Simon
Buchheiser Anja
Pohland Georg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waclawczyk Simon, Buchheiser Anja, Pohland Georg filed Critical Waclawczyk Simon
Priority to PCT/EP2012/061679 priority Critical patent/WO2013189521A1/en
Priority to PCT/EP2013/062805 priority patent/WO2013190013A1/en
Publication of WO2013189521A1 publication Critical patent/WO2013189521A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/067Hepatocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/067Hepatocytes
    • C12N5/0671Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/11Epidermal growth factor [EGF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/12Hepatocyte growth factor [HGF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/38Hormones with nuclear receptors
    • C12N2501/39Steroid hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60Transcription factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1369Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Definitions

  • the present invention relates to a method of generating cells of hepatocyte phenotype.
  • REACH Registration, Evaluation, Authorisation and Restriction of Chemical substances
  • manufacturers and importers are required to evaluate the risks associated with chemical compounds and to take measures regarding their control.
  • a particular challenge is assessing hepatotoxicity, since the physiological effects of many compounds only unfold once they are being degraded in the liver.
  • pharmaceutically active substances need to be tested for their hepatic effects.
  • Tests of xenobiotics and other compounds on their hepatic effects are currently generally based on animal models, i.e. the use of living animals or of cultured animal cells. Regardless of ethical concerns on animals, such model systems can only reflect human physiology to a limited extent. As a result, even after long and expensive test phases frequently unexpected adverse effects of pharmaceutical substances occur in humans during clinical trials or even after market entry.
  • An accepted alternative to animal models is the use of primary human hepatocytes. Due to the limited availability of donor material such methods can, however, only be carried out on a small scale. Further, differences in isolation procedure and in donor parameters (gender, genetic profile, medical condition, state of health) impede a standardisation of a test system based on primary human hepatocytes. In addition, human primary hepatocytes quickly lose their functions when cultured ex vivo.
  • carcinoma cell lines are being employed. Such cell lines are cost-effective, can be cultured and grown easily and are regularly available. However, liver specific functions such as the capability of detoxication are significantly reduced in these cells in comparison to hepatocytes. Hence, such cells are unsuitable for toxicological tests. In addition, the limited number of established carcinoma cell lines restricts genetic variability.
  • a further alternative to primary human hepatocytes is the use of adult stem cells. Differentiation of adult stem cells has, however, so far only yielded cells with limited hepatocyte-like properties. Due to their low functionality they are also not suitable for carrying out toxicological and pharmacological tests.
  • embryonic stem cells When differentiated, embryonic stem cells achieve a high degree of functionality, since these cells represent precursors of every human tissue and thus can theoretically be differentiated unlimitedly into any cell of the human body.
  • ethic concerns limit the use of embryonic stem cells in European countries such as Germany, as well as in the US substantially.
  • Induced pluripotent stem cells are regarded ethically uncritical.
  • the most effective method of generating iPS is retrovirally mediated overexpression. Nevertheless, this method only achieves an efficiency of 0.0001 to 0.1 %; in part it achieves only a partial reprogramming. Its low efficiency and reproducibility renders this method very time and cost intensive.
  • both embryonic stem cells and induced pluripotent stem cells are partially genetically unstable, and the factors used and induced, respectively, in differentiating them are associated with tumourigenesis, which affects the results of toxicological analysis.
  • the invention provides an in vitro method of generating cells of hepatocyte phenotype.
  • the method includes increasing in adherent adult multipotent cells the amounts of two transcription factors. These two transcription factors, the amounts of which are increased in the multipotent cells, are hepatocyte nuclear factor 6 (HNF- 6) and hepatocyte nuclear factor la (HNF-la).
  • HNF- 6 hepatocyte nuclear factor 6
  • HNF-la hepatocyte nuclear factor la
  • the method includes providing such adherent adult multipotent cells.
  • the method further includes increasing in the adherent adult multipotent cells the amount of the transcription factor hepatocyte nuclear factor 4a (HNF-4a) and/or increasing in the adherent adult multipotent cells the amount of the transcription factor hepatocyte nuclear factor 3 ⁇ (HNF-3 ).
  • the adult multipotent cells are in some embodiments mesenchymal stem cells, for instance mesenchymal stem cells of cord blood.
  • the invention provides a cell of hepatocyte phenotype.
  • the cell is obtained by the method according to the first aspect.
  • the invention provides a population of cells of hepatocyte phenotype.
  • the population of cells consists of, or in some embodiments includes, cells according to the second aspect.
  • the invention provides an in vitro method of testing the hepatic effect of a compound of interest.
  • the method includes contacting the cells of hepatic phenotype according to the second aspect with the compound of interest.
  • the method further includes assessing the viability and/or functionality of the cells of hepatocyte phenotype.
  • the method further includes determining the occurrence of apoptosis in the cells of hepatocyte phenotype.
  • the method further includes determining the cells' activity in generating at least one of serum albumin, fibrinogen, a clotting factor of the prothrombin group, bile, lipoprotein, transferrin, complement protein and glycoprotein.
  • the method includes determining the cells' activity in metabolizing homologous and/or heterologous compounds. In some embodiments testing the hepatic effect includes determining whether drug metabolizing phase I and phase II proteins can be induced or inhibited or whether transporter and receptor proteins of the cell can be induced or inhibited.
  • the invention relates to the use of cells of hepatocyte phenotype obtained by the method according to the first aspect for testing the hepatic effect of a compound of interest.
  • Testing the hepatic effect includes contacting the cells of hepatocyte phenotype with the compound of interest.
  • testing the hepatocyte effect further includes assessing the viability and/or functionality of the cells of hepatocyte phenotype.
  • the invention provides an in vitro method of forming a liver transplant.
  • the method includes allowing cells according to the first aspect to grow.
  • the method further includes forming a synthetic scaffold or a bioartificial liver device with the cells.
  • the method also includes culturing the cells in co-culture with at least one of endothelial cells, Kupffer cells, hepatic stellate cells, cholangiocytes, and fibroblasts.
  • the invention relates to a method of using cells of hepatocyte phenotype obtained by the method according to the first aspect in organ regeneration or replacement such as liver regeneration or replacement.
  • the invention relates to the use of cells of hepatocyte phenotype obtained by the method according to the first aspect for treating a hepatic disorder in a subject.
  • the hepatic disorder is hepatitis, a heredity disease and liver cirrhosis or liver cancer.
  • the heredity disease may for example be Wilson ' s disease, heamatochromatosis or alpha- 1 antitrypsin deficiency.
  • Figure 1 depicts immunocytochemical analysis of human cord blood derived unrestricted somatic stem cells (USSC) after transduction with hepatic transcription factors (magnification: 20X). The transcription factors were found to be located in the nucleus and thus physiologically active.
  • FIG. 2 depicts RT-PCR analysis of the expression of hepatocytic markers in transduced USSC after 4 days of expansion culture, before and after 12 days of differentiation culture.
  • the depicted results are representative data of two individual experiments using two different USSC populations (day 0: undifferentiated USSC after expansion culture; day 12: differentiated USSC, Hep.: human hepatocytes).
  • Hepatocyte cDNA was used as a positive control (+RT).
  • the corresponding first strand synthesis reaction mixture without reverse transcriptase represents the negative control (-RT).
  • Figure 3 shows the morphological changes of transduced USSC after 4 days of expansion culture and 12 days of differentiation culture (day 0: undifferentiated USSC after expansion culture; day 12: differentiated USSC).
  • Cells were transduced with the respective transcription factors HNFla, HNF-3p/FOXA2, HNF4a and HNF6.
  • FIG. 4 depicts data on the expression of hepatocytic genes of transduced USSC.
  • RT PCR analysis was carried out on transduced USSC after 12 days of differentiation culture.
  • H1-F-H4-H6 USSC transduced with HNFla, FOXA2, HNF4a, and HNF6
  • H1-F-H4 USSC transduced with HNFla, FOXA2 and HNF4a
  • F-H4-H6 USSC transduced with FOXA2 and HNF4a
  • F-H4 USSC transduced with FOXA2 and HNF4a.
  • cDNA of human hepatocytes was used as a positive control, the corresponding RT first strand synthesis reaction mixture represents the negative control.
  • Figure 5 depicts the morphology of transduced USSC following expansion culture (day 0) and differentiation culture for 12 days (day 12).
  • H 1 -F-H4-H6-US SC USSC transduced with HNFla, FOXA2, HNF4a, and HNF6;
  • H1-F-H4-USSC USSC transduced with HNFla, FOXA2 and HNF4a;
  • F-H4-H6-USSC USSC transduced with FOXA2 and HNF4a;
  • F-H4-USSC USSC transduced with F0XA2 and HNF4a.
  • Figure 6 shows that transduced USSC express a- 1 -Antitrypsin, a-1- Antitrypsin (AAT) is detected immunocytochemically in H1-F-H4-H6-USSC, H1-F-H4- USSC, F-H4-H6-USSC and F-H4-USSC after differentiation (HI : transduction with HNFla; F: transduction with FOXA2; H4: transduction with HNF4a; H6: transduction with HNF6; magnification of the lens: 20X).
  • HI transduction with HNFla
  • F transduction with FOXA2
  • H4 transduction with HNF4a
  • H6 transduction with HNF6
  • magnification of the lens 20X
  • nuclei/DNA are stained using DAPI.
  • Fig. 6 A is a greyscale representation of the image. Fig.
  • FIG. 6B is a greyscale representation of the image, in which only staining of a- 1 -Antitrypsin (FITC) is shown.
  • Fig. 6C is a greyscale representation of a copy of the image, in which only staining of nuclei using DAPI is shown. 20 % of the cells had a strong fluorescence staining. All other cells of the population could be weakly stained against AAT. F-H4-H6-USSC had 1 % AAT positive cells on day 12.
  • FITC a- 1 -Antitrypsin
  • Figure 7 depicts differences of H1-F-H4-H6-USSC, H1-F-H4-USSC, F-H4- H6-USSC and F-H4-USSC after 12 days of differentiation culture.
  • Assessment of gene expression of different markers is based on RT PCR (cf. Fig. 4), ++ indicates saturated bands, + indicates bands that are not saturated, +/- represents weak bands.
  • Indications on transduced USSC populations are based on cells counts of strong fluorescent cells in relation to DAPI stained nuclei following immunocytochemical analysis. In H1-F-H4-USSC cultures 12 % of strongly AAT positive cells were detected. In cultures of F-H4-USSC less than 0.5 % of cells were strongly positive for AAT.
  • Figure 8 depicts the expression of hepatocyte transcription factors by transduced USSC. RT-PCR analysis of endogenous transcription factors was carried out on USSC transduced with HNFla, FOXA2, HNF4a and HNF6 (H1-F-H4-H6-USSC). cDNA of human hepatocyets and pooled vectors (each 1 pg of plasmid) were used as positive controls.
  • FIG. 9 shows that transduced USSC express human serum albumin (ALB).
  • ALB is detected immunocytochemically in H1-F-H4-H6-USSC before (dayO) and after differentiation (dayl2).
  • pUC2-USSC Mock-transduced USSC
  • Rhodamine-conjugated antibodies were used to detect human serum albumin; DNA was detected by DAPI-staining.
  • FIG. 10 demonstrates, that a-fetoprotein (AFP) is neither expressed in Mock- transduced USSC (pUC2-USSC) nor in H1-F-H4-H6-USSC before (dayO) and after differentiation (dayl2).
  • Fluorescein isothiocyanate (FITC)-conjugated antibodies were used to detect human a-fetoprotein; DNA was detected by DAPI-staining.
  • Figure 11 shows the sequences of primers used in the generation of data shown in the preceding Figures. SEQ ID NOs are indicated in parentheses.
  • Figure 12 demonstrates performance of hepatocyte functions by H1-F-H4-H6- USSC.
  • Albumin secretion and urea production were calculated by referring concentrations in supernatants to durance of medium condition and total protein amount of analyzed cells.
  • Induction of CYP3 A4 activity was analyzed by addition of rifampicin in to culture medium for 48 hours before measurements, (d: day, h: hour, RLU: relative light units, RIF: rifampicin).
  • A Albumin secretion of H1-F-H4-H6-USSC measured by enzyme-linked immunosorbent assay (ELISA).
  • a method of generating a cell of hepatocyte phenotype according to the invention can be taken to define a method of forward programming an adherent adult multipotent cell.
  • Forward programming refers to an alteration in the differentiation status of a cell, typically by increasing expression of one or more lineage-determining genes in the multipotent cell.
  • Forward programming may differ from directed differentiation, where an increased expression of endogenous genes is induced by adding growth factors or certain low molecular weight molecules to the culture medium.
  • the growth factors or low molecular weight molecules signal though cell surface proteins and surface protein-mediated signalling to activate endogenous pathways toward the lineage desired.
  • programming factor genes for differentiation are activated directly, thereby by-passing the cell surface proteins and surface protein-mediated signalling pathways.
  • the word "programming" refers to a process that changes a cell to form progeny of at least one cell type different from the original cell and, either in culture or in vivo, different from it would have under the same conditions without programming. This means that after sufficient proliferation, a measurable proportion of progeny having phenotypic characteristics of the new cell type if essentially no such progeny could form before programming.
  • a method of the invention is a method of differentiating adherent adult multipotent cells.
  • "Differentiation" is a process known to those skilled in the art by which a less specialized cell becomes a more specialized cell type.
  • the question of how adult non-hepatic stem cells are converted into hep atocyte- like cells in vivo is so far unsettled. Originally it was assumed that the so called plasticity of cells allows differentiation into hepatocyets.
  • a method of the present invention provides one or more cells of a hepatic phenotype, namely of hepatocyte phenotype. Such cells may also be addressed as hepatocyte- like cells.
  • the term phenotype is understood in the art to refer to detectable characteristics of a cell or organism. These characteristics in particular include the morphology, the development, the biochemical and/or physiological properties, phenology, and behaviour.
  • the phenotype thus includes inter alia the molecules, such as proteins that are present within and on the surface of a cell.
  • the term phenotype is typically contrasted to the genotype, which refers to heredity.
  • the characteristics defining the phenotype are the manifestation of gene expression.
  • a hepatocyte is a cell of a cell type that makes up 70-80% of the cytoplasmic mass of the liver. Hepatocytes are involved in protein synthesis, protein storage, transformation of carbohydrates, synthesis of cholesterol, bile salts and phospholipids, and the detoxification, modification and excretion of exogenous and endogenous substances. Hepatocytes generate serum albumin, fibrinogen, and the prothrombin group of clotting factors. A hepatocyte also initiates the formation and secretion of bile. Hepatocytes are also the main site for the synthesis of lipoproteins, ceruloplasmin, transferrin, complement and glycolproteins.
  • hepatocytes have the ability to metabolize, detoxify, and inactivate exogenous compounds such as drugs and insecticides, and endogenous compounds such as steroids.
  • Characteristics of a hepatocyte phenotype include the expression of cell markers, enzymatic activity, and the characterization of morphological features and intercellular signalling. Where for example a plurality of characteristics of hepatocytes is present in a single cell, the cell may be regarded as being of hepatocyte phenotype.
  • Morphological features characteristic of hepatocytes include a polygonal cell shape, a binucleate phenotype, the presence of rough endoplasmic reticulum for synthesis of secreted protein, the presence of Golgi-endoplasmic reticulum lysosome complex for intracellular protein sorting, the presence of peroxisomes and glycogen granules, relatively abundant mitochondria, and the ability to form tight intercellular junctions resulting in creation of bile canalicular spaces.
  • Characteristics of a hepatocyte phenotype may also be assessed on the basis of the presence of phenotypic markers (see below), i.e. particular molecules and/or moieties of molecules found in or on the cell, typically on the cell surface. Assessment of the level of expression of markers can be determined in comparison to a reference to other cells.
  • phenotypic markers see below
  • markers of mature hepatocytes there may be used for instance adult hepatocytes of the species of interest may be used.
  • Negative controls may for example include cells of a different lineage, such as lymphocytes or fibroblasts. Protein and oligosaccharide determinants characteristic of a hepatocyte phenotype may be detected using any known methodology available, such as immunological techniques, e.g.
  • Suitable techniques include Western blot analysis, for instance of a cellular extract, an enzyme-linked immunoassay, a radioimmunoassay or a fluorescence titration assay, which may for example be carried out on a cellular extract or a medium in which the cells are being cultured.
  • a radioimmunoassay is based on the measurement of radioactivity associated with a complex formed between an antibody or a proteinaceous binding molecule with antibody-like functions and an antigen
  • an ELISA is based on the measurement of an enzymatic reaction associated with a complex formed between an antibody or a proteinaceous binding molecule with antibody-like functions and an antigen.
  • An immunological technique relies on the use of antibodies or binding molecules with antibody-like functions, typically being proteinaceous binding molecules.
  • An antibody is an immunoglobulin or a fragment thereof.
  • immunoglobulin fragments are Fab fragments, Fv fragments, single-chain Fv fragments (scFv), diabodies, triabodies (Iliades, P., et al, FEBS Lett (1997) 409, 437-441), decabodies (Stone, E., et al, Journal of Immunological Methods (2007) 318, 88-94) and other domain antibodies (Holt, L.J., et al, Trends Biotechnol. (2003), 21, 11, 484-490).
  • a proteinaceous binding molecule with antibody-like functions is a mutein based on a polypeptide of the lipocalin family (WO 2003/029462; WO 2005/019254; WO 2005/019255; WO 2005/019256; Beste et al, Proc. Natl. Acad. Sci. USA (1999) 96, 1898-1903).
  • Lipocalins such as the bilin binding protein, the human neutrophil gelatinase-associated lipocalin, human Apo lipoprotein D, human tear lipocalin, or glycodelin, posses natural ligand-binding sites that can be modified so that they bind to selected small protein regions known as haptens.
  • proteinaceous binding molecules include, but are not limited to, the so-called glubodies (see WO 96/23879), proteins based on the ankyrin scaffold (Mosavi, L.K., et al, Protein Science (2004) 13, 6, 1435-1448) or the crystalline scaffold (WO 2001/04144), the proteins described by Skerra (J. Mol. Recognit. (2000) 13, 167-187), AdNectins, tetranectins, avimers and peptoids.
  • Avimers contain so called A-domains that occur as strings of multiple domains in several cell surface receptors (Silverman, J, et al, Nature Biotechnology (2005) 23, 1556-1561).
  • Adnectins derived from a domain of human fibro- nectin, contain three loops that can be engineered for immunoglobulin-like binding to targets (Gill, D.S. & Damle, N.K., Current Opinion in Biotechnology (2006) 17, 653-658).
  • Tetranectins derived from the respective human homotrimeric protein, likewise contain loop regions in a C-type lectin domain that can be engineered for desired binding (ibid.).
  • Peptoids which can act as protein ligands, are oligo(N-alkyl) glycines that differ from peptides in that the side chain is connected to the amide nitrogen rather than the a carbon atom.
  • Peptoids are typically resistant to proteases and other modifying enzymes and can have a much higher cell permeability than peptides (see e.g. Kwon, Y.-U., and Kodadek, T., J. Am. Chem. Soc. (2007) 129, 1508-1509).
  • an antibody or a molecule with antibody-like functions may be used that is linked to an attached label, such as for instance in Western analysis or ELISA.
  • an intracellular immunoglobulin may be used for detection.
  • a further technique that can also be carried out to detect the presence of phenotypic markers is Fluorescence Microscopy, including Ratio Fluorescence Microscopy. In ratio fluorescence microscopy two fluorescence images are collected and the parameter of interest is quantified as a ratio of the fluorescence in one image to that in the other image.
  • a further technique suitable for detecting the presence of phenotypic markers on the surface of cells is fluorescence resonance energy transfer (FRET). In FRET an excited fluorescent donor molecule, rather than emitting light, transfers that energy via a dipole-dipole interaction to an acceptor molecule in close proximity.
  • FRET fluorescence resonance energy transfer
  • acceptor fluorescence due to FRET is accompanied by an increase in acceptor fluorescence (i.e., for example, sensitized emission).
  • acceptor fluorescence i.e., for example, sensitized emission.
  • the amount of FRET depends strongly on distance, typically decreasing as the sixth power of the distance, so that fluorophores can directly report on phenomena occurring on the scale of a few nanometers, well below the resolution of optical microscopes.
  • FRET has been used to map distances and study aggregation states, membrane dynamics, or DNA hybridization.
  • a further characteristic of a hepatocyte phenotype that may be assessed is bile secretion. Detection of biliary secretion may for instance be done using the so called fluorescein diacetate time lapse assay. In this technique the cells of interest are incubated with doxycycline and fluorescein diacetate, a non- fluorescent precursor of fluorescein. Uptake and metabolization to fluorescein is then determined. As two further characteristic of a hepatocyte phenotype, glycogen synthesis and the cell's ability to store glycogen may be determined.
  • a cell is termed multipotent if it has the potential to give rise to cells from multiple, but a limited number of lineages of an organism.
  • multipotent cells include, but are not limited to, stem cells and progenitor cells.
  • a "totipotent" cell is a cell with the potential to differentiate into any type of somatic or germ cell found in the organism.
  • any desired cell may be derived, by some means, from a totipotent cell.
  • unipotent cells can produce only one cell type. Any of the terms unipotent, multipotent and totipotent generally refer to an undifferentiated cell or a partially differentiated cell.
  • an undifferentiated cell examples include, but are not limited to, a stem cell, e.g. an embryonic stem cell, including a mammalian embryonic stem cell, such as a human, a mouse, a rat or a Guinea pig embryonic stem cell, any of which may also be a cell of an embryonic stem cell line.
  • a stem cell may also be a trophoblast stem cell or any extraembryonic stem cell, e.g. an adult stem cell, also called a somatic stem cell.
  • Further examples of an undifferentiated cell include a germ cell, an oocyte, a blastomer, and an inner cell mass cell.
  • the adult multipotent cells have been obtained from a host organism such as a fish, an amphibian, a bird or a mammal.
  • the adherent adult multipotent cell is a stem cell.
  • the stem cell is a somatic stem cell. Somatic stem cells have been identified in most organ tissues.
  • a somatic stem cell is a hemato- poietic stem cell, which is a mesoderm-derived cell that can be purified based on cell surface markers and functional characteristics.
  • the hematopoietic stem cell isolated from bone marrow, blood, cord blood, fetal liver and yolk sac, is the progenitor cell that reinitiates hematopoiesis for the life of a recipient and generates multiple hematopoietic lineages.
  • hematopoietic stem cells When transplanted into lethally irradiated animals or humans, hematopoietic stem cells can repopulate the erythroid, neutrophil-macrophage, megakaryocyte and lymphoid hematopoietic cell pool. In vitro, hematopoietic stem cells can be induced to undergo at least some self-renewing cell divisions and can be induced to differentiate to the same lineages as is seen in vivo.
  • the stem cell is a cord blood stem cell such as a mesenchymal stem cell (MSC) or an unrestricted somatic stem cell (USSC).
  • MSC mesenchymal stem cell
  • USSC unrestricted somatic stem cell
  • a mesenchymal stem cell may also be of umbilical cord tissue or of entirely different origin, such as adipose tissue, muscle tissue, placenta tissue or the dental pulp of deciduous baby teeth.
  • a mesenchymal stem cell has cell surface molecules such as CD73, CD90 and CD 105 that are typical mesenchymal cell surface proteins.
  • a mesenchymal stem cell also has fibroblastoid morphology and shows adherent growth on plastic surfaces.
  • a mesenchymal stem cell originally derived from the embryonic mesoderm and isolated from adult bone marrow, is known to be able to differentiate to form muscle, bone, cartilage, fat, marrow stroma or tendon.
  • the stem cell may be one of a gastrointestinal stem cell, an epidermal stem cell, a neural stem cell or a hepatic stem cell, also termed oval cell.
  • the stem cells has been isolated from umbilical cord, placenta, amniotic fluid, chorion villi, blastocysts, bone marrow, adipose tissue, brain, peripheral blood, the gastrointestinal tract, cord blood, blood vessels, skeletal muscle, skin, liver or menstrual blood.
  • An example of a cell that is a partially differentiated cell is a progenitor cell.
  • a progenitor cell which may be unipotent or multipotent, has a capacity to differentiate into a specific type of cell and a limited ability of self-renewal, which it cannot maintain.
  • Further examples of a partially differentiated cell include, but are not limited to, a precursor cell, i.e. a stem cell that has developed to the stage where it is committed to forming a particular kind of new cell, a lineage-restricted stem cell, and a somatic stem cell.
  • the cell may be obtained or derived from any host organism.
  • the cell may be directly taken from a respective host organism in form of a sample such as e.g. a biopsy or a blood sample. It may also have been derived from a host organism and subsequently been cultured, grown, transformed or exposed to a selected treatment.
  • the host organism from which the cell is derived or obtained may be any organism such as a microorganism, an animal, such as a fish, an amphibian, a reptile, a bird, a mammal, including a rodent species, an invertebrate species, e.g. of the subclass Lissamphibia that includes e.g.
  • mammals include, but are not limited to, a rat, a mouse, a rabbit, a guinea pig, a squirrel, a hamster, a vole, a platypus, a dog, a goat, a horse, a pig, an elephant, a chicken, a macaque, a chimpanzee and a human.
  • the method of the invention includes assessing the absence of undifferentiated cells or cells not entirely differentiated, for example by using an antibody that specifically binds to a polypeptide cell surface marker present in undifferentiated cells but not in cells of hepatocyte phenotype.
  • the protein or polypeptide cell surface marker present on the surface of undifferentiated cells but not in cells of hepatocyte phenotype is at least one of CXCR4, CD10, CD13, CD41a (gpllbllla), CD34, CD56, CD90, CDl lO, CD117, CD123, CD133, CD135, CD277 and CD318, at least one of CD10, CD13, CD56, and an MHC Class-I cell surface antigen, and/or at least one of CD3, CD5, CD7, CDl lb, CD14, CD15, CD16, CD19, CD25, CD45, and CD65.
  • the method of the invention includes isolating and/or identifying cells of hepatocyte phenotype by positive or negative selection using an antibody or a proteinaceous binding molecule with antibody-like functions, as indicated above.
  • the cells can for instance be identified and/or isolated by fluorescent activated cell sorting (FACS) or affinity column chromatography.
  • FACS fluorescent activated cell sorting
  • affinity column chromatography affinity column chromatography.
  • the cells can also be identified on the basis of identifying plasma membrane proteins by mass spectrometry or other suitable techniques.
  • any progenitor cell may be used in this method of the invention.
  • suitable progenitor cells include, but are not limited to, neuronal progenitor cells, endothelial progenitor cells, erythroid progenitor cells, cardiac progenitor cells, oligodendrocyte progenitor cells, retinal progenitor cells, or hematopoietic progenitor cells.
  • the amount of two or more transcription factors in the respective cell is increased.
  • the amount which may also be referred to as the level of the respective protein, indicates the absolute number of molecules of the transcription factors in the cell.
  • a method according to the invention includes increasing the cellular amount of the transcription factor hepatocyte nuclear factor 6 (HNF-6), also called one cut domain family member 1 (OC-1) or one cut homeobox 1.
  • HNF-6 transcription factor hepatocyte nuclear factor 6
  • OC-1 cut domain family member 1
  • the protein HNF-6 may be any respective variant or isoform of the respective species, e.g. human.
  • the protein may for example be the human protein of the Swissprot/Uniprot accession number Q9UBC0 (version 107 as of 18 April 2012, SEQ ID NO: 59), the murine protein of the Swissprot/Uniprot accession number 008755 (version 113 as of 18 April 2012, SEQ ID NO: 60), the rat protein of the Swissprot/Uniprot accession number P70512 (version 93 as of 18 April 2012, SEQ ID NO: 61), the bovine protein represented by the fragment of the Swissprot/Uniprot accession number Q5DM44 (version 41 as of 21 March 2012, SEQ ID NO: 62), the protein of the rhesus macaque (Macaca mulatta) of the Swissprot/Uniprot accession number G7MXH6 (version 2 as of 21 March 2012, SEQ ID NO: 63) or the protein of the crab-eating macaque (Cynomolgus monkey, Macaca fascicularis) of the Swissprot/
  • a natural variant of the human FINF-6 protein is named VAR 010729 in the data base entry of Swissprot/Uniprot accession number Q9UBC0, having an alanine instead of a proline at position 75 of the amino acid sequence.
  • the sequence of the rat FINF-6 protein depicted as the canonical sequence in the data base entry of Swissprot/Uniprot accession number P70512 has the identifier P70512-1 and is also called the isoform alpha.
  • a further isoform, called the isoform beta has the identifier P70512-2, also named VSP 002312, in this data base entry.
  • isoform alpha it differs from isoform alpha in that it has the sequence Ala Glu Ser Ala Met Gly Gly Ser Val Pro Ser Leu Arg He Thr Ser Gly Gly Pro Gin Leu Ser Val Pro Pro Leu Pro instead of an alanine at position 368 of the sequence defining Swissprot/Uniprot accession number P70512-1.
  • FINF-6 may be the protein encoded by the ONECUT1 (one cut homeobox 1) gene, also called FTNF6, HNF-6 or HNF6A, for example the human gene of GenBank Gene ID No 3175 as of 06 May 2012, the mouse gene of GenBank Gene ID No 15379 as of 20 April 2012, the rat gene of GenBank Gene ID No 25231 as of 20 April 2012 or the bovine gene of GenBank Gene ID No 503584 as of 10 May 2012.
  • a further transcription factor is the transcription factor hepatocyte nuclear factor la (FTNF-la), also called liver-specific transcription factor LF-B1 or sometimes simply transcription factor 1 (TCF-1).
  • FTNF-la transcription factor hepatocyte nuclear factor la
  • the protein FiNF-la may be any respective variant or isoform of the respective species, e.g. human.
  • FiNF-la is the human protein of the Swissprot/ Uniprot accession number P20823 (version 157 as of 18 April 2012, SEQ ID NO: 65), the mouse protein of the Swissprot/Uniprot accession number P22361 (version 126 as of 18 April 2012, SEQ ID NO: 66), the rat protein of the Swissprot/Uniprot accession number P15257 (version 129 as of 18 April 2012, SEQ ID NO: 67), the chicken protein of the Swissprot/Uniprot accession number Q90867 (version 92 as of 13 June 2012, SEQ ID NO: 68) or the salmon (Salmo salar) protein of the Swissprot/Uniprot accession number Q91474 (version 77 as of 18 April 2012, SEQ ID NO: 69).
  • the sequence of the human FiNF-la depicted as the canonical sequence in the data base entry of Swissprot/Uniprot accession number P20823 has the identifier P20823-1 and is also called the isoform A.
  • Two further isoforms, called isoforms B and C, have the identifiers P20823-2 and P20823-3 in this data base entry.
  • Isoform B differs from isoform A firstly in that it has the sequence Gly Glu His Pro Val Pro His Thr Ala Gly ... Ala Cys Val Ser Gly Thr Ser Val Phe Pro instead of the sequence Ala Leu Tyr Ser His Lys Pro Glu Val Ala ...
  • Isoform B differs from isoform A in that it does not contain the amino acids 543 to 601 of the amino acid sequence.
  • Isoform C firstly differs from isoform A in that it has the sequence Lys Leu Val Gly Met Gly Gly His Leu Gly ... Ser His Cys Ala Thr Ser Val He Pro Gly instead of the sequence Leu Ala Ser Thr Gin Ala Gin Ser Val Pro ... Thr Gin Ser Pro Phe Met Ala Thr Met Ala at positions 438 to 494 of the amino acid sequence.
  • Isoform C differs from isoform A in that it does not contain the amino acids 495 to 601 of the amino acid sequence present in isoform A.
  • HNF-la may be the protein encoded by the FINF1A gene, for example the human gene of GenBank Gene ID No 6927 as of 06 May 2012, the mouse gene of GenBank Gene ID No 21405 as of 06 May 2012, the rat gene of GenBank Gene ID No 24817 as of 20 April 2012, the chicken gene of GenBank Gene ID No 416967as of 17 March 2012 or the Xenopus laevis gene of GenBank Gene ID No 378589 as of 12 November 2012.
  • FTNF-4a hepatocyte nuclear factor 4a
  • NRF-14 nuclear receptor subfamily 2 group A member 1
  • TCF-14 simply transcription factor 14
  • the protein FTNF-4a may be any respective variant or isoform of the respective species, e.g. human.
  • the protein may for example be the human protein of the Swissprot/Uniprot accession number P41235 (version 147 as of 18 April 2012, SEQ ID NO: 75), the mouse protein of the Swissprot/Uniprot accession number P49698 (version 117 as of 18 April 2012, SEQ ID NO: 76), the rat protein of the Swissprot/Uniprot accession number P22449 (version 123 as of 18 April 2012, SEQ ID NO: 77) or the Xenopus laevis protein of the Swissprot/Uniprot accession number Q91766 (version 90 as of 18 April 2012, SEQ ID NO: 78).
  • the sequence of the human FINF-4a depicted as the canonical sequence in the data base entry of Swissprot/Uniprot accession number P41235 has the identifier P41235-1 and is also called FINF-4al or the isoform FINF4-B.
  • Six further isoforms, called isoforms HNF-4a2 or HNF-4A, HNF-4a3 or HNF-4C, HNF-4a4, HNF-4a7, HNF-4a8 and HNF-4a9 have the identifiers P41235-2, P41235-3, P41235-4, P41235-5, P41235-6 and P41235-7 in this data base entry.
  • FINF-4a2 differs from FINF-4al in that it has only a single serine instead of the sequence Cys Glu Trp Pro Arg Pro Arg Gly Gin Ala Ala at positions 418 to 428 of the amino acid sequence.
  • FINF-4a3 differs from FINF-4al in that it has the sequence Pro Cys Gin Ala Gin Glu Gly Arg Gly Trp ... Ser Pro Leu Cys Arg Phe Gly Gin Val Ala instead of the sequence Ser Pro Ser Asp Ala Pro His Ala His His His ... Gin Pro Thr He Thr Lys Gin Glu Val He at positions 378 to 474 of the amino acid sequence.
  • HNF-4a4 differs from HNF-4al in that it contains the sequence Asn Asp Leu Leu Pro Leu Arg Leu Ala Arg Leu Arg His Pro Leu Arg His His Trp Ser He Ser Gly Gly Val Asp Ser Ser Pro Gin Gly instead of the asparagine at position 38 of the amino acid sequence.
  • HNF-4a7 differs from HNF-4al in that it has the N- terminal sequence Met Val Ser Val Asn Ala Pro Leu Gly Ala Pro Val Glu Ser Ser Tyr instead of the sequence Met Arg Leu Ser Lys Thr Leu Val Asp Met Asp Met Ala Asp Tyr Ser Ala Ala Leu Asp Pro Ala Tyr Thr Thr Leu Glu Phe Glu Asn Val Gin Val Leu Thr Met Gly Asn at positions 1 to 38 of the amino acid sequence.
  • HNF-4a8 differs from HNF-4al firstly in that it has the N-terminal sequence Met Val Ser Val Asn Ala Pro Leu Gly Ala Pro Val Glu Ser Ser Tyr instead of the sequence Met Arg Leu Ser Lys Thr Leu Val Asp Met Asp Met Ala Asp Tyr Ser Ala Ala Leu Asp Pro Ala Tyr Thr Thr Leu Glu Phe Glu Asn Val Gin Val Leu Thr Met Gly Asn at positions 1 to 38 of the amino acid sequence.
  • HNF-4a8 differs from HNF- 4a 1 in that it contains only a serine instead of the sequence Cys Glu Trp Pro Arg Pro Arg Gly Gin Ala Ala at the sequence positions 418 to 428 of the amino acid sequence.
  • HNF-4a9 differs from HNF-4al firstly in that it has the N-terminal sequence Met Val Ser Val Asn Ala Pro Leu Gly Ala Pro Val Glu Ser Ser Tyr instead of the sequence Met Arg Leu Ser Lys Thr Leu Val Asp Met Asp Met Ala Asp Tyr Ser Ala Ala Leu Asp Pro Ala Tyr Thr Thr Leu Glu Phe Glu Asn Val Gin Val Leu Thr Met Gly Asn at positions 1 to 38 of the amino acid sequence.
  • HNF-4a9 differs from HNF-4al in that it has the sequence Pro Cys Gin Ala Gin Glu Gly ArgGly Trp ... Ser Pro Leu Cys Arg Phe Gly Gin Val Ala instead of the sequence Ser Pro Ser Asp Ala Pro His Ala His His His ... Gin Pro Thr He Thr Lys Gin Glu Val He at positions 378 to 474 of the amino acid sequence.
  • the sequence of the mouse HNF-4a depicted as the canonical sequence in the data base entry of Swissprot/Uniprot accession number P49698 has the identifier P49698-1 and is also called the long isoform.
  • the short isoform with the identifier P49698-2 differs from the long isoform in that it has a serine instead of the sequence Cys Glu Trp Pro Arg Pro Arg Gly Gin Ala Ala at positions 418 to 428 of the amino acid sequence.
  • HNF-4a is in some embodiments the protein encoded by the HNF4A gene, for example the human gene of GenBank Gene ID No 3172 as of 06 May 2012, the mouse gene of GenBank Gene ID No 15378 as of 06 May 2012, the rat gene of GenBank Gene ID No 25735 as of 06 May 2012, the bovine gene of GenBank Gene ID No 25735 as of 06 May 2012 or the horse gene of GenBank Gene ID No 100056007 as of 16 November 2011.
  • a further transcription factor is the transcription factor hepatocyte nuclear factor 3 ⁇ (HNF-3 ), also called Forkhead box protein A2 (FOXA2) or sometimes transcription factor 3B (TCF-3B).
  • HNF-3 may be any respective variant or isoform of the respective species, e.g. human.
  • the protein may for example be the human protein of the Swissprot/Uniprot accession number Q9Y261 (version 120 as of 18 April 2012, SEQ ID NO: 70), the mouse protein of the Swissprot/Uniprot accession number P35583 (version 112 as of 18 April 2012, SEQ ID NO: 71), the rat protein of the Swissprot/Uniprot accession number P32182 (version 104 as of 18 April 2012, SEQ ID NO: 72), the protein of Medaka fish (Japanese ricefish, Oryzias latipes) of the Swissprot/Uniprot accession number 042097 (version 79 as of 18 April 2012, SEQ ID NO: 73) or the chicken protein of the Swissprot/ Uniprot accession number Q9PWP8 (version 76 as of 18 April 2012, SEQ ID NO: 74).
  • the human protein of the Swissprot/Uniprot accession number Q9Y261 version 120 as of 18 April 2012, SEQ ID NO: 70
  • the sequence of the human HNF-3 protein depicted as the canonical sequence in the data base entry of Swissprot/Uniprot accession number Q9Y261 has the identifier Q9Y261-1 and is also called isoform 1.
  • a further isoform, isoform 2 has the identifier Q9Y261-2 in this data base entry. It differs from isoform 1 in that it has the sequence Met His Ser Ala Ser Ser Met instead of the N-terminal (i.e., position 1) methionine of the amino acid sequence of Swissprot/Uniprot accession number Q9Y261-1.
  • HNF-3 may be the protein encoded by the HNF3B gene, also called the foxa2 gene, for example the human gene of GenBank Gene ID No 15376 as of 20 April 2012, the zebra fish gene of GenBank Gene ID No 30126 as of 29 April 2012, the mouse gene of GenBank Gene ID No 15376 as of 20 April 2012, the rat gene of GenBank Gene ID No 25099 as of 20 April 2012 or the Xenopus laevis gene of GenBank Gene ID No 100127318 as of 24 December 2011.
  • a variant of any of the above transcription factors includes a protein with a high sequence identity to a respective known form of the transcription factor.
  • a corresponding sequence of a variant that has a high sequence identity to a known form of the protein has in some embodiments at least 65 %, at least 70 %, at least 75 %, at least 80 %, at least 82 %, at least 85 %, at least 87 %, at least 90% identity, including at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 99.5% identity to the sequence of the known form of the protein.
  • identity is meant a property of sequences that measures the similarity or relationship of the variant and the corresponding known protein. Identity is measured by dividing the number of identical residues by the total number of residues and multiplying the product by 100.
  • Blast Altschul, et al. (1997) Nucleic Acids Res. 25, 3389-3402)
  • Blast2 Altschul, et al. (1990) J. Mol. Biol. 215, 403-410
  • Smith- Waterman Smith, et al. (1981) J. Mol. Biol. 147, 195-197.
  • a variant of a known protein may include one or more mutations - relative to the sequence of the known protein form.
  • a respective variant may in some embodiments have been obtained from the sequence of a known protein form by molecular biology techniques, including recombinant techniques.
  • a variant has a sequence that contains a substitution (or replacement) that is a conservative substitution, not being associated with a change in biological activity. Nevertheless, any substitution - including non-conservative substitution or one or more from the exemplary substitutions listed below - is envisaged as long as the variant retains its capability of acting as a transcription factor with the same specificity as the known form of the protein, respectively, and/or it has an identity to the then substituted sequence in that it is at least 60%>, such as at least 65%>, at least 70%>, at least 75%>, at least 80%>, at least 85 % or higher identical to the "original" sequence.
  • Conservative substitutions are generally the following substitutions, listed according to the amino acid to be mutated, each followed by one or more replacement(s) that can be taken to be conservative: Ala— Gly, Ser, Val; Arg— Lys; Asn— Gin, His; Asp— Glu; Cys ⁇ Ser; Gin ⁇ Asn; Glu ⁇ Asp; Gly ⁇ Ala; His ⁇ Arg, Asn, Gin; He ⁇ Leu, Val; Leu ⁇ He, Val; Lys ⁇ Arg, Gin, Glu; Met ⁇ Leu, Tyr, He; Phe ⁇ Met, Leu, Tyr; Ser ⁇ Thr; Thr— Ser; Trp— Tyr; Tyr— Trp, Phe; Val— He, Leu.
  • Other substitutions are also permissible and can be determined empirically or in accord with other known conservative or non-conservative substitutions.
  • the following eight groups each contain amino acids that can typically be taken to define conservative substitutions for one another:
  • substitutions can be expected to increase the likelihood of a change in biological activity, representing more substantial changes: Ala— Leu, He; Arg ⁇ Gin; Asn ⁇ Asp, Lys, Arg, His; Asp ⁇ Asn; Cys ⁇ Ala; Gin ⁇ Glu; Glu ⁇ Gin; His ⁇ Lys; He ⁇ Met, Ala, Phe; Leu ⁇ Ala, Met, Norleucine; Lys ⁇ Asn; Met ⁇ Phe; Phe ⁇ Val, He, Ala; Trp ⁇ Phe; Tyr ⁇ Thr, Ser; Val ⁇ Met, Phe, Ala.
  • the amount of at least two transcription factors is increased, as already explained above.
  • Increasing the amount/level of a transcription factor in a cell according to the invention may be achieved by increasing the formation and/or by reducing the degradation of the transcription factor in the cell.
  • Increasing the formation of a transcription may be achieved by activating and/ or enhancing one or more homologous, i.e. endogenous, genes encoding the transcription factor.
  • Increasing the formation of a transcription may also be achieved by increasing the expression of a homologous, but transcriptionally repressed transcription factor, by reversing the silencing or inhibitory effect on the expression of a transcription factor gene, for example by regulating the upstream transcription factor expression or epigenetic modulation.
  • the method of the invention includes introducing into the cell a nucleic acid molecule, typically a heterologous nucleic acid molecule, encoding the respective transcription factor, capable of allowing expression of the same in the cell.
  • the method in such embodiments further includes expressing the heterologous transcription factor.
  • nucleic acid molecule refers to any nucleic acid in any possible configuration, such as single stranded, double stranded or a combination thereof.
  • Nucleic acids include for instance DNA molecules, RNA molecules, analogues of the DNA or RNA generated using nucleotide analogues or using nucleic acid chemistry, locked nucleic acid molecules (LNA), protein nucleic acids molecules (PNA), alkylphosphonate and alkylphosphotriester nucleic acid molecules and tecto-RNA molecules (e.g. Liu, B., et al, J. Am. Chem. Soc. (2004) 126, 4076-4077).
  • LNA locked nucleic acid molecules
  • PNA protein nucleic acids molecules
  • alkylphosphonate and alkylphosphotriester nucleic acid molecules tecto-RNA molecules
  • DNA or RNA may be of genomic or synthetic origin and may be single or double stranded.
  • Such nucleic acid can be e.g. mRNA, cRNA, synthetic RNA, genomic DNA, cDNA synthetic DNA, a copolymer of DNA and RNA, oligonucleotides, etc.
  • a respective nucleic acid may furthermore contain non-natural nucleotide analogues and/or be linked to an affinity tag or a label.
  • a PNA molecule is a nucleic acid molecule in which the backbone is a pseudopeptide rather than a sugar. Accordingly, PNA generally has a charge neutral backbone, in contrast to DNA or RNA.
  • PNA is capable of hybridising at least complementary and substantially complementary nucleic acid strands, just as e.g. DNA or RNA (to which PNA is considered a structural mimic).
  • LNA has a modified RNA backbone with a methylene bridge between C4' and 02', providing the respective molecule with a higher duplex stability and nuclease resistance.
  • Alkylphosphonate and alkylphosphotriester nucleic acid molecules can be viewed as a DNA or an RNA molecule, in which phosphate groups of the nucleic acid backbone are neutralized by exchanging the P-OH groups of the phosphate groups in the nucleic acid backbone to an alkyl and to an alkoxy group, respectively.
  • DNA or RNA may be of genomic or synthetic origin and may be single or double stranded.
  • Such nucleic acid can be e.g. mRNA, cRNA, synthetic RNA, genomic DNA, cDNA synthetic DNA, a copolymer of DNA and RNA, oligonucleotides, etc.
  • a respective nucleic acid may furthermore contain non-natural nucleotide analogues and/or be linked to an affinity tag or a label.
  • nucleotide analogues are known and can be used in nucleic acids used in a method of the invention, for example as a heterologous nucleic acid introduced into a cell.
  • a nucleotide analogue is a nucleotide containing a modification at for instance the base, sugar, or phosphate moieties.
  • a substitution of 2'-OH residues of siRNA with 2'F, 2'O-Me or 2 ⁇ residues is known to improve the in vivo stability of the respective RNA.
  • Modifications at the base moiety include natural and synthetic modifications of A, C, G, and T/U, different purine or pyrimidine bases, such as uracil-5-yl, hypoxanthin-9-yl, and 2- aminoadenin-9-yl, as well as non-purine or non-pyrimidine nucleotide bases.
  • Other nucleotide analogues serve as universal bases.
  • Universal bases include 3-nitropyrrole and 5 -nitro indole. Universal bases are able to form a base pair with any other base. Base modifications often can be combined with for example a sugar modification, such as for instance 2'-0-methoxyethyl, e.g. to achieve unique properties such as increased duplex stability.
  • a heterologous sequence e.g. a gene, encoding a transcription factor, such as HNF- ⁇ or HNF-6, may be introduced into an adherent adult multipotent cell.
  • the sequence which may be included in a heterologous nucleic acid molecule, may be introduced into the cell by means of recombinant technology.
  • the sequence may be included in any gene delivery system such as for instance a transposon system, a viral gene delivery system, an episomal gene delivery system or a homologous recombination system such as utilizing a zinc finger nuclease, a transcription activator-like effector (TALE) nuclease, or a meganuclease.
  • TALE transcription activator-like effector
  • a heterologous nucleic acid molecule that has a sequence encoding a transcription factor may in some embodiments be included in a vector, typically as a vector carrying a gene of the transcription factor. It may in this regard be advantageous to further use a vector that contains a promoter effective to initiate transcription in the respective host cell (whether of endogenous or heterologous origin).
  • the present invention also relates to the use of such a nucleic acid molecule, e.g. a respective vector or included therein, for increasing the absolute quantity of a transcription factor in a cell.
  • vector sometimes also referred to as gene delivery system or gene transfer vehicle, relates to a macromolecule or complex of molecules that include(s) a polynucleotide to be delivered to a host cell, whether in vitro, ex vivo or in vivo.
  • a vector is a single or double-stranded circular nucleic acid molecule that allows or facilitates the transfer of a nucleic acid sequence into a cell.
  • a vector can generally be transfected into cells and replicated within or independently of a cell genome.
  • a circular double-stranded nucleic acid molecule can be cut and thereby linearized upon treatment with restriction enzymes.
  • a nucleic acid molecule encoding a transcription factor, such as HNF- ⁇ or FINF-6, can be inserted into a vector by cutting the vector with restriction enzymes and ligating the two pieces together.
  • a vector may for instance be a viral vector, such as a retroviral vector, a Lentiviral vector, a herpes virus based vector or an adenoviral vector.
  • a vector may also be a plasmid vector or a liposome-based extrachromosomal vector, also called episomal vector.
  • Lymphotrophic herpes virus is a herpes virus which replicates in a lymphoblast and becomes a plasmid for a part of its natural life-cycle.
  • a vector may also be based on an organically modified silicate.
  • a vector may be a transposon-based system, i.e. a transposon/transposase system, such as the so called Sleeping Beauty, the Frog Prince transposon - transposase system or the TTAA-specific transposon piggyBac system.
  • Transposons are mobile genetic elements in that they are sequences of DNA that can move around to different positions within the genome of a single cell, a process called transposition. In the process, a transposon can cause mutations and change the amount of DNA in the genome.
  • the amount of a transcription factor, e.g. FINF-6 or FINF- ⁇ , in a cell can be increased by enhancing the expression of homologous FINF-6 and FINF- ⁇ , respectively.
  • Micro-RNA molecules termed miR-495 and miR-218 target the 3 '-untranslated region of FINF-6 (Simion, A, et al., Biochem Biophys Res Commun. (2010) 391, 1, 293-298), reducing its expression. Such micro-RNA molecules can be silenced, i.e.
  • a suitable antagomir a small RNA molecule of a length of typically 20 to 25 nucleotides, directed against the micro-RNA, into the respective cell
  • a suitable antagomir a small RNA molecule of a length of typically 20 to 25 nucleotides, directed against the micro-RNA
  • the expression of a homologous transcription factor e.g. FINF-6
  • FINF-6 can also be decreased, for instance where different heterologous FINF-6 is being expressed in a cell.
  • Such reduction of the amount of homologous FINF-6 can for instance be achieved by means of a micro-RNA or small interfering RNA (siRNA) molecule directed against the transcription factor.
  • RNA interference represents a cellular mechanism that protects the genome.
  • SiRNA and miRNA molecules mediate the degradation of their complementary RNA by association of the siRNA with a multiple enzyme complex to form what is called the RNA- induced silencing Complex (RISC).
  • RISC RNA- induced silencing Complex
  • siRNAs are perfectly base paired to the corresponding complementary strand, while miRNA duplexes are imperfectly paired. Activation of RISC leads to the loss of expression of the respective gene (for a brief overview see Zamore, PD, Haley, B Science [2005], 309, 1519-1524). It has been observed that the strongest silencing occurs with sequences that do not form secondary structures (Patzel, V., et al. Nature Biotech. [2005] 23, 1440-1444). Persons skilled in the art thus typically avoid using sequences that for instance are known to form a loop. This can be done by exchanging selected bases to a base that is still able to form a wobble pairing with the target sequence (Patzel, V et al, supra).
  • the siR A/miRNA technique has for example been applied to silencing parasitic DNA sequences, such as the cleavage of HIV RNA, as disclosed in US patent application 2005/0191618.
  • a respective siRNA/shRNA/miRNA molecule may be directly synthesized or expressed within a cell of interest, for example by means of a vector under the control of an inducible or constitutive promoter. It may also be introduced into a respective cell and/or delivered thereto.
  • a siRNA, shRNA or miRNA molecule into selected cells in vivo is its non- covalent binding to a fusion protein of a heavy-chain antibody fragment (F a3 ⁇ 4 ) and the nucleic acid binding protein protamin (Song, E. et al, Nature Biotech. (2005), 23, 6, 709-717).
  • Another illustrative example of delivering a siRNA molecule into selected cells in vivo is its encapsulation into a liposome.
  • Morrissey et al. Nature Biotech. (2005), 23, 8, 1002-1007 for instance used a stable nucleic acid-lipid-particle, coated with a polyethylene glycol-lipid conjugate, to form liposomes for intravenous administration.
  • nanoparticles for delivering siRNA or miRNA a suitable approach of their cell-specific targeting has been described by Weissleder et al. ⁇ Nature Biotech. (2005), 23, 11 , 1418-1423).
  • a further example of delivering a siRNA, shRNA or miRNA molecule to a selected target cell is the use of a biological vehicle such as a bacterium or a virus that includes the respective nucleic acid molecule.
  • a biological vehicle such as a bacterium or a virus that includes the respective nucleic acid molecule.
  • Xiang et al ⁇ Nature Biotech. (2006), 24, 6, 697-702 have for instance used this approach by administering the bacterium E. coli, which transcribed from a plasmid inter alia both shRNA and invasin, thus permitting entry into mammalian cells and subsequent gene silencing therein
  • promoter refers to a nucleic acid sequence needed for gene sequence expression. Promoter regions vary from organism to organism, but are well known to persons skilled in the art for different organisms. For example, in prokaryotes, the promoter region contains both the promoter (which directs the initiation of RNA transcription) as well as the DNA sequences which, when transcribed into RNA, will signal synthesis initiation. Such regions will normally include those 5'-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, and the CAAT sequence.
  • a nucleic acid may be introduced into the multipotent cells by any suitable technique of nucleic acid delivery for transformation of a cell available in the art.
  • suitable techniques include, but are not limited to, direct delivery of DNA, e.g. via transfection, injection, including microinjection, electroporation, calcium phosphate precipitation, by using DEAE-dextran followed by polyethylene glycol, direct sonic loading, liposome mediated transfection, receptor-mediated transfection, microprojectile bombardment, agitation with silicon carbide fibers, Agrobacterium-mediated transformation, desiccation/inhibition-mediated DNA uptake or any combination thereof.
  • a method according to the invention may further include measuring the expression of a gene encoding the (heterologous) transcription factor. This can for instance be achieved by determining the number of RNA molecules transcribed from a gene that is under the control of the respective promoter.
  • a method commonly used in the art is the subsequent copy of RNA to cDNA using reverse transcriptase and the coupling of the cDNA molecules to a fluorescent dye. The analysis may for example be performed in form of a DNA microarray. Numerous respective services and kits are commercially available, for instance GeneChip® expression arrays from Affymetrix.
  • Other means of determining gene expression of a transcription factor include, but are not limited to, an oligonucleotide array, and quantitative Real-time Polymerase Chain Reaction (RT-PCR).
  • a method according to the invention additionally includes the comparison of obtained results with those of one or more control measurements.
  • a control measurement may include any condition that varies from the main measurement itself. It may include conditions of the method under which for example no expression of the respective gene occurs.
  • a further means of a control measurement is the use of a mutated form of a respective gene, for example a gene not encoding the corresponding transcription factor, or encoding a non- functional transcription factor protein.
  • a method according to the invention may further include a selection or enrichment step for the cells of hepatocyte phenotype obtained by forward programming or differentiation as described above.
  • the adult multipotent cells employed in a method of the invention such as the pluripotent stem cells or progeny cells thereof, may have a selectable or screenable reporter expression cassette with a reporter gene.
  • expression cassette is meant a combination of the respective gene, including a transcriptional termination sequence, and a suitable transcriptional promoter.
  • the reporter expression cassette may include a hepatocyte-specific transcriptional regulatory element operably linked to a reporter gene.
  • Non-limiting examples of hepatocyte-specific transcriptional regulatory element include a promoter of albumin, a 1 -antitrypsin (AAT), cytochrome p450 3A4 (CYP3A4), apo lipoprotein A-I, or apoE.
  • AAT 1 -antitrypsin
  • CYP3A4 cytochrome p450 3A4
  • apo lipoprotein A-I apoE.
  • a mature hepatocyte-specific transcriptional regulatory element may include a promoter of albumin, a 1 -antitrypsin, asialoglycoprotein receptor, cytokeratin 8 (CK8), cytokeratin 18 (CK18), CYP3A4, fumaryl acetoacetate hydrolase (FAH), glucose-6-phosphates, tyrosine aminotransferase, phosphoenol- pyruvate carboxykinase, and tryptophan 2,3-dioxygenase.
  • Selection or enrichment of cells of hepatocyte phenotype may further include a step of determining whether the cell of interest expresses a hepatocyte reporter gene or one or more hepatocyte characteristics as described herein.
  • Characteristics of the cells of hepatocyte phenotype include, but are not limited to one or more of the expression of one or more hepatocyte markers, the activity of liver-specific enzymes, the production of by-products of liver specific reactions such as bile and urea or bile secretion, or xenobiotic detoxification, morphological features characteristic of hepatocytes or in vivo liver engraftment in an immunodeficient subject.
  • Two illustrative examples of a liver-specific enzymes the activity of which may be determined, are glucose-6-phosphatase and CYP3A4.
  • Hepatocyte markers that may be analysed include, but are not limited to, HNF-3 , HNF-4a, cytochrome p450 3 A4 (CYP3A4), Bile Salt Export Pump (BSEP) glucose-6-phosphatase (G6PC), fructose- 1,6- bisphosphatase (FBP1), glycogen synthase 2 (GYS2), farnesoid X receptor (FXR), arginase Type 1 (ARG1), albumin such as human serum albumin (ALB) or a combination thereof.
  • G6PC glucose-6-phosphatase
  • FBP1 fructose- 1,6- bisphosphatase
  • GYS2 glycogen synthase 2
  • FXR farnesoid X receptor
  • ARG1 arginase Type 1
  • albumin such as human serum albumin (ALB) or a combination thereof.
  • Suitable markers are a 1 -antitrypsin (AAT), cytokeratin 8 (CK8), cytokeratin 18 (CK18), asialoglycoprotein receptor (ASGR), alcohol dehydrogenase 1 and liver-specific organic anion transporter (LST-1).
  • Fig. 2 illustrates the analysis of the expression of the hepatocyte markers HNF- ⁇ , HNF-3 , HNF-4a, HNF6, CYP3A4, BSEP, G6PC, FBP1, GYS2, FXR, ARG1, and ALB by way of RT-PCR with subsequent agarose gel electrophoresis. HNF6 expression could not be detected in samples where this transcription factor had not been heterologously introduced into the cell.
  • the canalicular transporter BSEP was expressed in all cells following differentiation.
  • G6PC showed weak expression in all cell samples.
  • FBP1 a further gene encoding an enzyme of gluconeogenesis, was strongly expressed in differentiated cells transduced with HNF6.
  • expression of ARGl could only be detected in cells transduced with FINF6 following differentiation.
  • a respective method may include adding the respective compound, typically a predetermined quantity thereof, to the cells of hepatocyte phenotype.
  • the compound of interest is dissolved in a fluid, typically a liquid, which is then being added to the medium that encompasses the cells of hepatocyte phenotype.
  • a method according to the present invention includes contacting a cell of hepatocyte phenotype with a predetermined quantity of a compound of interest.
  • a predetermined quantity of a compound of interest In some embodiments at least two different predetermined quantities of a compound of interest are used. In some of these embodiments at least a first and a second cell of hepatocyte phenotype are used. The first cell is contacted with the lower of the two predetermined quantities and the second cell is contacted with the higher of the two predetermined quantities.
  • Respective embodiments may for example be a screening assay, a cytotoxity test or the determination of a dose/response curve.
  • any desired matter may be tested for its effect on hepatic cells based on the use of cells obtained as described above.
  • the matter may include or be a low molecular weight compound, such as a pharmaceutically active compound.
  • the matter may be a nutrient, a saccharide, an oligosaccharide, a polysaccharide, a vitamin, a nucleotide, an oligonucleotide, a polynucleotide or a combination of any of these examples.
  • the matter may be tested may be any sample, such as, but not limited to, a soil sample, an air sample, an environmental sample, a cell culture sample, a bone marrow sample, a rainfall sample, a fallout sample, a sewage sample, a ground water sample, an abrasion sample, an archaeological sample, a food sample, an infection sample, a nosocomial infection sample, a production sample, a drug preparation sample, a biological molecule production sample, a protein preparation sample, a lipid preparation sample, a carbohydrate preparation sample, a space sample, an extraterrestrial sample or any combination thereof.
  • the sample may furthermore have been prepared in form of a fluid, such as a solution.
  • Examples include, but are not limited to, a solution or a slurry of a nucleotide, a polynucleotide, a nucleic acid, a peptide, a polypeptide, an amino acid, a protein, a synthetic polymer, a biochemical composition, an organic chemical composition, an inorganic chemical composition, a metal, a lipid, a carbohydrate, a combinatory chemistry product, a drug candidate molecule, a drug molecule, a drug metabolite or of any combinations thereof.
  • Further examples include, but are not limited to, a suspension of a metal, a suspension of metal alloy, and a solution of a metal ion or any combination thereof, as well as a suspension of a cell, a virus, a microorganism, a pathogen, a radioactive compound or of any combinations thereof. It is understood that a sample may furthermore include any combination of the aforementioned examples.
  • compounds may be used in the form of a library.
  • libraries are collections of various small organic molecules, chemically synthesized as model compounds, or nucleic acid molecules containing a large number of sequence variants.
  • a screening process In embodiments where a plurality of candidate compounds are analysed for their hepatic effect according to a method of the present invention such an embodiment may typically called a screening process. These candidate compounds may be analysed independent from each other, e.g. concurrently, consecutively or in any way out of phase. The candidate compounds may for example be added to a cell culture medium. In some embodiments any number of steps of analysing a plurality of candidate compounds may for example be carried out automatically - also repeatedly, using for instance commercially available robots. For such purposes any number of automation devices may be employed, for instance an automated readout system, a pipetting robot, a rinsing robot, or a fully automated screening system.
  • the process may be an in-vitro screening process, for example carried out in multiple-well microplates (e.g. conventional 48-, 96-, 384- or 1536 well plates) using one or more automated work stations.
  • the invention provides a process of high-throughput screening.
  • the method may also be carried out using a kit of parts, for instance designed for performing the present method.
  • cells of hepatocyte phenotype of a corresponding species are provided according to the invention as described above.
  • the cells of hepatocyte phenotype are contacted with the matter of interest.
  • the cells are then incubated with the matter of interest, i.e. the contact of the cells with the matter is maintained.
  • Testing the effect of matter on the liver i.e. the hepatic effect, generally further includes assessing the viability and/or functionality of the cells of hepatocyte phenotype.
  • the effect of matter may be monitored over a certain period of time, such as over a period from about 1 hour to about a week, e.g. 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 days or 6 days.
  • the functionality of the cells of hepatocyte phenotype may be assessed by measuring any hepatocyte characteristic function, such as of the above illustrated functions.
  • the viability of the cells may be assessed by any suitable technique.
  • microscopic analysis may be carried out, for example by determining the cellular morphology.
  • Microscopic analysis may for example include determining the presence of signs selected from the group consisting of cellular stress, factor toxicity, cellular viability, and cellular death.
  • the level of one or more metabolites indicative of cell viability may also be assessed in this regard.
  • Two illustrative examples of a metabolite the intracellular level of which may be determined are urea or ammonia.
  • Three illustrative examples of a protein the expression of which may be determined are liver albumin, beta galactosidase, and cytochrome P450.
  • apoptosis occurs, including is being initiated are progresses, in one or more cells of hepatocyte phenotype following contact with the compound of interest.
  • Apoptosis is a programmed cell death and typically a mechanism in a multicellular organism to remove undesired cells.
  • An apoptotic cell shows a characteristic morphology, by which it can be identified under a microscope.
  • the occurrence and/or progress of apoptosis in a tumour cell may be monitored, for example by propodium iodide staining, Annexin V-FITC staining, flow cytometry analysis, or combinations thereof, as well as by determining mitochondrial dysfunction or caspase 3 activation.
  • Testing the hepatic effect may include contacting the cells of hepatocyte phenotype with one or more selected test compounds.
  • such a method may further include determining whether metabolites of the test compounds or of other compounds, whether heterologously applied or homologously present.are formed.
  • the formed metabolites, including the amount of formed metabolites and the pattern of metabolites generated, may then be compared to a reference experiment.
  • a reference experiment may include cells that have not been contacted with the selected test compound(s) but have been contacted with test compound carrier substances.
  • testing the hepatic effect includes determining the formation, in particular determining functional characteristics of the formation, of serum albumin, of fibrinogen, and at least one of the prothrombin group of clotting factors. Testing the hepatic effect may also include determining the formation and secretion, in particular determining functional characteristics of the formation and secretion of bile, lipoprotein, transferrin or complement proteins. Testing the hepatic effect may also include determining whether the cells synthesize, in particular determining functional characteristics of the synthesis of, glycoprotein or urea.As indicated above, testing the hepatic effect may include analysis of the metabolization of homologous and/or heterologous compounds.
  • the metabolization of homologous and/or heterologous compounds in hepatocyets and hepatocyte-like cells is carried out by so called drug-metabolizing enzymes, enzymes that catalyze the biotransformation of for instance drugs and xenobiotics.
  • testing the hepatic effect may include determining test compound induction or inhibition of drug metabolizing phase I and phase II proteins or transporter and receptor proteins.
  • drug-metabolizing enzymes can be classified into two main groups: oxidative or conjugative.
  • Phase I reactions also termed nonsynthetic reactions, include, but are not limited to, oxidation, reduction, hydrolysis, cyclization and decyclization, addition of oxygen or removal of hydrogen.
  • the reactions are carried out by mixed function oxidases.
  • a typical reaction in a Phase I oxidation involves conversion of a C-H bond to a C-OH.
  • a well known example of an oxidative group of enzymes that mediate phase I reactions are the NADPH- cytochrome P450 reductase (P450R)/cytochrome P450 (P450) electron transfer systems.
  • Conjugation reactions are known as phase II reactions and are usually detoxicating in nature, typically involving the interactions of the polar functional groups of phase I metabolites.
  • Conjugation may for instance occur with glucuronic acid, a sulfonate, glutathione, acetate or an amino acid.
  • glucuronic acid a sulfonate
  • glutathione a sulfonate
  • glutathione a sulfonate
  • glutathione a sulfonate
  • glutathione a sulfonate
  • glutathione glutathione
  • acetate amino acid
  • testing the hepatic effect of a compound of interest includes analysing whether phase I and/or phase II proteins of the cell can be induced or inhibited.
  • phase I and/or phase II proteins of the cell can be induced or inhibited.
  • Such induction or reduction of activity and or amount of enzymes in hepatocytes is well known in the art.
  • the expression of CYP1 genes can be induced via the aryl hydrocarbon receptor (AhR) which dimerizes with the AhR nuclear trans locator, in response to many poly cyclic aromatic hydrocarbon (PAHs).
  • AhR aryl hydrocarbon receptor
  • PAHs poly cyclic aromatic hydrocarbon
  • Xenobiotics such as phenobarbital-like compounds (CAR), dexamethasone and rifampin-type of compounds (PXR) are known to cause the steroid family of orphan receptors, the constitutive androstane receptor (CAR) and pregnane X receptors (PXR) to heterodimerize with the retinoid X receptor (RXR) and transcriptionally activate the promoters of CYP2B and CYP3A gene expression.
  • CAR phenobarbital-like compounds
  • PXR rifampin-type of compounds
  • phase II gene inducers include, but are not limited to, butylated hydroxyanisol (BHA), tertbutylhydroquinone (tBHQ), green tea polyphenol (GTP), (-)-epicatechin-3-gallate (EGCG) and the isothiocyanates (PEITC, sulforaphane).
  • BHA butylated hydroxyanisol
  • tBHQ tertbutylhydroquinone
  • GTP green tea polyphenol
  • EGCG epigallate
  • PEITC isothiocyanates
  • MPK mitogen-activated protein kinase
  • ARE / EpRE antioxidant / electrophile response element enhancers that are found in many phase II drug- metabolizing enzymes as well as many cellular defensive enzymes such as thioredoxins, GCS and HO-1, with the subsequent induction of gene expression of these genes.
  • cells of hepatocyte phenotype are cultured in co-culture with at least one of endothelial cells, Kupffer cells, hepatic stellate cells, cholangiocytes and fibroblasts.
  • the invention also provides a method of identifying a hepatic pathogen.
  • hepatic pathogen refers to any pathogen, such as a bacterial, viral or parasitic pathogen, that is capable of infecting cells of the liver, in particular hepatocytes.
  • the invention also provides a method of treating a subject in need of an increase in liver function.
  • the method includes administering to the subject cells of hepatocyte phenotype obtained as described above. Thereby liver function is increased.
  • cells may be grown two-dimensionally, e.g. in a monolayer, or three- dimensionally, for example in the extracellular matrix.
  • Cells of hepatocyte phenotype obtained as described above may also be used for applications in spheroid and/or organoid cultures and synthetic scaffolds or bioartificial liver devices.
  • the cells of hepatocyte phenotype may be used for therapeutic applications of at least one of viral or toxin mediated hepatitis, heredity diseases such as Wilson ' s disease, heamatochromatosis or alpha- 1 antitrypsin deficiency, and liver cirrhosis or liver cancer.
  • the cells of hepatocyte phenotype are cultured in co-culture with endothelial cells, with Kupffer cells, hepatic stellate cells, cholangiocytes and/or fibroblasts (supra).
  • Cord blood not suitable for clinical banking was, from a plurality of donors, applied for stromal stem cell generation in accordance with informed donor consent. Isolation of mononuclear cells (MNC), selective culture of MNC for USSC-generation and USSC- expansion were performed as described previously [Kogler, G., et al, J Exp Med (2004) 200, 2, 123-135].
  • MNC mononuclear cells
  • Sequences coding for human hepatocytes nuclear factor la (FINFla), forkhead box A2 (FOXA2), hepatocytes nuclear factor 4a (FINF4a) and hepatocytes nuclear factor 6 (FINF6) were generated by PCR amplification of hepatocyte cDNA.
  • Primers containing specific restriction sites were used to allow cloning of cDNA into the multiple cloning site of pUC2CL6IN-plasmid.
  • Each forward-primer contained a kozak consensus sequence (GCCACC).
  • HNFla and HNF4a cDNAs were inserted into ECORI and BAMHI restriction sites of pUC2CL6IN (Primer 5 ' - 3 ' : HNF 1 a-forward: AAAGAATTCGCCACC ATGGTTTCTAAAC TGAGCCAG (SEQ ID NO: 31), HNF la-reverse: TTTGGATCCGGTTACTGGGAGGA AGAGG (SEQ ID NO: 32); FOXA2-forward: AAAGCTAGCGCCACCATGCTGGGAG CGGTGAAG (SEQ ID NO: 33), FOXA2-reverse: AAAGG ATCCTTTCTTCTCCCTTGCGT CTC (SEQ ID NO: 34); HNF4 a- forward: AAAGAATTCGCCACCATGCGACTCTCCAAA ACCCT (SEQ ID NO: 35), HNF4a-reverse: TTTGGATCCCCCCAAGCCCCAGCGGCTTG (SEQ ID NO: 36); HNF6-forward: AAACTCGAGGCCACCATGAACGCGCAG
  • FOXA2 was inserted into NHEI and BAMHI restriction sites of pUC2CL6IN.
  • HNF6 was inserted into XHOI and BAMHI restriction sites of pUC2CL6IN.
  • plasmids were combined with packaging plasmid pCD/NLBH and envelope plasmid pALF- GALV and integrated by FUGENE-transfection (Roche, Mannheim, Germany) into Hek293T cells for lentiviral production. After 24 hrs, supernatants containing lentiviruses were collected and passed through a 45 ⁇ syringe- filter (Fischer Scientific, Schrö, Germany).
  • Immunofluorescence analysis cells were differentiated on Chamber Slides (Fischer Scientific, Schrö, Germany), washed with PBS, fixed with 3.6% paraformaldehyde for 15 min at room temperature and permeabilized with methanol for 5 min at -20°C.
  • Antibodies applied were: mouse anti HNF4a (clone K9218, Perseus Proteomics, dilution 1 :200), mouse anti HNF6 (clone 4F12, Novus, dilution 1 :200), rabbit anti FOXA2 (#3143, Cell signalling, dilution 1 :800), rabbit anti HNFla (sc- 10791, Santa Cruz, dilution 1 :200).
  • RNA isolation and reverse transcription polymerase chain reaction (RT-PCR)
  • RNA isolation from cell lines and cell populations was performed applying RNeasy Mini Kit with additional on-column DNase digestion (Qiagen, Hilden, Germany).
  • Total human fetal liver RNA (MVPTM Total RNA, pooled from male donors, gestation weeks 18 - 20) was purchased from Stratagen (La Jo 11a, CA, USA). 0.5-1.0 ⁇ g of total RNA was reversely transcribed afterwards into cDNA using SuperScriptlll (Invitrogen, Düsseldorf, Germany), according to manufacturer's instructions.
  • Quantitative real time PCR was carried out by setting up reactions in triplicates, containing SYBR® Green PCR Mastermix (Applied Biosystems, Darmstadt, Germany), 0.2 ⁇ of each primer as well as 50 ng of reverse transcribed total RNA, and subsequent analysis on ABI prism 7700 real-time PCR system (Applied Biosystems, Darmstadt, Germany). All qPCR results refer to the (housekeeping) gene Glyceraldehyde-3- phosphate dehydrogenase (GAPDH). Analyses correspond to a minimum of 3 independently isolated RNA samples per time point of differentiation. Primer sequences are listed in Fig. 11.
  • CYP3A4 activity was performed applying the P450-GloTM CYP3A4- Assay (Promega, Mannheim, Germany). Inducible CYP3A4 activity was determined by culturing differentiated cells with or without 25 ⁇ rifampicin (Sigma-Aldrich, Schnelldorf, Germany) for 48 hrs before testing. Prior to testing, cells were washed twice with PBS and incubated in HDM containing luciferin-PFBE substrate (50 ⁇ ) for 3-4 hrs. Subsequently, 50 ⁇ of supernatant were mixed in equal parts with luciferin detection reagent, incubated for 20 min and measured with a tube-luminometer (Berthold Analytical, Nashua, USA).
  • Hepatocyte functions of transduced USSC were analyzed by determining the amount of human albumin and urea in cell culture supernatants or by evaluating CYP3A4 substrate metabolization by transduced USSC.
  • Albumin secretion, urea production and inducible cytochrome-p450-3A4 activity as performed by transduced USSC demonstrated functional activity of transduced USSC in a hepatocyte specific manner. This designates the cells of hepatocyte phenotype described herein as suitable alternatives for hepatocyte based applications.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides an in vitro method of generating cells of hepatic phenotype, the method comprising increasing in adherent adult multipotent cells the amount of the transcription factor hepatocyte nuclear factor 6 and the amount of the transcription factor hepatocyte nuclear factor 1α.

Description

METHOD OF GENERATING CELLS OF HEPATOCYTE PHENOTYPE
[0001] The present invention relates to a method of generating cells of hepatocyte phenotype.
[0002] Under the European Community Regulation on chemicals and their safe use, termed "REACH" for Registration, Evaluation, Authorisation and Restriction of Chemical substances, manufacturers and importers are required to evaluate the risks associated with chemical compounds and to take measures regarding their control. A particular challenge is assessing hepatotoxicity, since the physiological effects of many compounds only unfold once they are being degraded in the liver. In addition, pharmaceutically active substances need to be tested for their hepatic effects.
[0003] Tests of xenobiotics and other compounds on their hepatic effects are currently generally based on animal models, i.e. the use of living animals or of cultured animal cells. Regardless of ethical concerns on animals, such model systems can only reflect human physiology to a limited extent. As a result, even after long and expensive test phases frequently unexpected adverse effects of pharmaceutical substances occur in humans during clinical trials or even after market entry. An accepted alternative to animal models is the use of primary human hepatocytes. Due to the limited availability of donor material such methods can, however, only be carried out on a small scale. Further, differences in isolation procedure and in donor parameters (gender, genetic profile, medical condition, state of health) impede a standardisation of a test system based on primary human hepatocytes. In addition, human primary hepatocytes quickly lose their functions when cultured ex vivo.
[0004] As an alternative to primary human hepatocytes, in research often carcinoma cell lines are being employed. Such cell lines are cost-effective, can be cultured and grown easily and are regularly available. However, liver specific functions such as the capability of detoxication are significantly reduced in these cells in comparison to hepatocytes. Hence, such cells are unsuitable for toxicological tests. In addition, the limited number of established carcinoma cell lines restricts genetic variability. A further alternative to primary human hepatocytes is the use of adult stem cells. Differentiation of adult stem cells has, however, so far only yielded cells with limited hepatocyte-like properties. Due to their low functionality they are also not suitable for carrying out toxicological and pharmacological tests.
[0005] When differentiated, embryonic stem cells achieve a high degree of functionality, since these cells represent precursors of every human tissue and thus can theoretically be differentiated unlimitedly into any cell of the human body. However, ethic concerns limit the use of embryonic stem cells in European countries such as Germany, as well as in the US substantially.
[0006] Induced pluripotent stem cells (iPS) are regarded ethically uncritical. The most effective method of generating iPS is retrovirally mediated overexpression. Nevertheless, this method only achieves an efficiency of 0.0001 to 0.1 %; in part it achieves only a partial reprogramming. Its low efficiency and reproducibility renders this method very time and cost intensive.
[0007] In addition, both embryonic stem cells and induced pluripotent stem cells are partially genetically unstable, and the factors used and induced, respectively, in differentiating them are associated with tumourigenesis, which affects the results of toxicological analysis.
[0008] Thus, there remains a need for an alternative human or animal based method that can be used for testing chemical compounds on their hepatic effects. It would be advantageous if such a method could circumvent species specific particularities or allow for genetic variability, be at hand at any time and/or reduce the number of animal tests needed. Accordingly it is an object of the present invention to provide a respective method. This object is solved by a method of forming cells according to claim 1.
[0009] According to a first aspect, the invention provides an in vitro method of generating cells of hepatocyte phenotype. The method includes increasing in adherent adult multipotent cells the amounts of two transcription factors. These two transcription factors, the amounts of which are increased in the multipotent cells, are hepatocyte nuclear factor 6 (HNF- 6) and hepatocyte nuclear factor la (HNF-la). Typically the method includes providing such adherent adult multipotent cells.
[0010] In some embodiments only the amounts of these two transcription factors are being increased in the cells. According to a particular embodiment of the first aspect, the method further includes increasing in the adherent adult multipotent cells the amount of the transcription factor hepatocyte nuclear factor 4a (HNF-4a) and/or increasing in the adherent adult multipotent cells the amount of the transcription factor hepatocyte nuclear factor 3β (HNF-3 ). The adult multipotent cells are in some embodiments mesenchymal stem cells, for instance mesenchymal stem cells of cord blood.
[0011] According to a second aspect, the invention provides a cell of hepatocyte phenotype. The cell is obtained by the method according to the first aspect. [0012] According to a third aspect, the invention provides a population of cells of hepatocyte phenotype. The population of cells consists of, or in some embodiments includes, cells according to the second aspect.
[0013] According to a fourth aspect, the invention provides an in vitro method of testing the hepatic effect of a compound of interest. The method includes contacting the cells of hepatic phenotype according to the second aspect with the compound of interest. Typically the method further includes assessing the viability and/or functionality of the cells of hepatocyte phenotype. In some embodiments the method further includes determining the occurrence of apoptosis in the cells of hepatocyte phenotype.
[0014] According to a particular embodiment of the fourth aspect, the method further includes determining the cells' activity in generating at least one of serum albumin, fibrinogen, a clotting factor of the prothrombin group, bile, lipoprotein, transferrin, complement protein and glycoprotein. According to a further embodiment of the fourth aspect, the method includes determining the cells' activity in metabolizing homologous and/or heterologous compounds. In some embodiments testing the hepatic effect includes determining whether drug metabolizing phase I and phase II proteins can be induced or inhibited or whether transporter and receptor proteins of the cell can be induced or inhibited.
[0015] According to a related fifth aspect, the invention relates to the use of cells of hepatocyte phenotype obtained by the method according to the first aspect for testing the hepatic effect of a compound of interest. Testing the hepatic effect includes contacting the cells of hepatocyte phenotype with the compound of interest. Typically testing the hepatocyte effect further includes assessing the viability and/or functionality of the cells of hepatocyte phenotype.
[0016] According to a sixth aspect, the invention provides an in vitro method of forming a liver transplant. The method includes allowing cells according to the first aspect to grow. In some embodiments the method further includes forming a synthetic scaffold or a bioartificial liver device with the cells. In some embodiments the method also includes culturing the cells in co-culture with at least one of endothelial cells, Kupffer cells, hepatic stellate cells, cholangiocytes, and fibroblasts.
[0017] According to a related seventh aspect, the invention relates to a method of using cells of hepatocyte phenotype obtained by the method according to the first aspect in organ regeneration or replacement such as liver regeneration or replacement. [0018] According to an eighth aspect, the invention relates to the use of cells of hepatocyte phenotype obtained by the method according to the first aspect for treating a hepatic disorder in a subject. In some embodiments the hepatic disorder is hepatitis, a heredity disease and liver cirrhosis or liver cancer. The heredity disease may for example be Wilson's disease, heamatochromatosis or alpha- 1 antitrypsin deficiency.
[0019] The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and the accompanying drawings, in which:
[0020] Figure 1 depicts immunocytochemical analysis of human cord blood derived unrestricted somatic stem cells (USSC) after transduction with hepatic transcription factors (magnification: 20X). The transcription factors were found to be located in the nucleus and thus physiologically active.
[0021] Figure 2 depicts RT-PCR analysis of the expression of hepatocytic markers in transduced USSC after 4 days of expansion culture, before and after 12 days of differentiation culture. The depicted results are representative data of two individual experiments using two different USSC populations (day 0: undifferentiated USSC after expansion culture; day 12: differentiated USSC, Hep.: human hepatocytes). Hepatocyte cDNA was used as a positive control (+RT). The corresponding first strand synthesis reaction mixture without reverse transcriptase represents the negative control (-RT).
[0022] Figure 3 shows the morphological changes of transduced USSC after 4 days of expansion culture and 12 days of differentiation culture (day 0: undifferentiated USSC after expansion culture; day 12: differentiated USSC). Cells were transduced with the respective transcription factors HNFla, HNF-3p/FOXA2, HNF4a and HNF6.
[0023] Figure 4 depicts data on the expression of hepatocytic genes of transduced USSC. RT PCR analysis was carried out on transduced USSC after 12 days of differentiation culture. H1-F-H4-H6: USSC transduced with HNFla, FOXA2, HNF4a, and HNF6; H1-F-H4: USSC transduced with HNFla, FOXA2 and HNF4a; F-H4-H6: USSC transduced with FOXA2 and HNF4a; F-H4: USSC transduced with FOXA2 and HNF4a. cDNA of human hepatocytes was used as a positive control, the corresponding RT first strand synthesis reaction mixture represents the negative control.
[0024] Figure 5 depicts the morphology of transduced USSC following expansion culture (day 0) and differentiation culture for 12 days (day 12). H 1 -F-H4-H6-US SC : USSC transduced with HNFla, FOXA2, HNF4a, and HNF6; H1-F-H4-USSC: USSC transduced with HNFla, FOXA2 and HNF4a; F-H4-H6-USSC: USSC transduced with FOXA2 and HNF4a; F-H4-USSC: USSC transduced with F0XA2 and HNF4a.
[0025] Figure 6 shows that transduced USSC express a- 1 -Antitrypsin, a-1- Antitrypsin (AAT) is detected immunocytochemically in H1-F-H4-H6-USSC, H1-F-H4- USSC, F-H4-H6-USSC and F-H4-USSC after differentiation (HI : transduction with HNFla; F: transduction with FOXA2; H4: transduction with HNF4a; H6: transduction with HNF6; magnification of the lens: 20X). In addition, nuclei/DNA are stained using DAPI. Fig. 6 A is a greyscale representation of the image. Fig. 6B is a greyscale representation of the image, in which only staining of a- 1 -Antitrypsin (FITC) is shown. Fig. 6C is a greyscale representation of a copy of the image, in which only staining of nuclei using DAPI is shown. 20 % of the cells had a strong fluorescence staining. All other cells of the population could be weakly stained against AAT. F-H4-H6-USSC had 1 % AAT positive cells on day 12.
[0026] Figure 7 depicts differences of H1-F-H4-H6-USSC, H1-F-H4-USSC, F-H4- H6-USSC and F-H4-USSC after 12 days of differentiation culture. Assessment of gene expression of different markers is based on RT PCR (cf. Fig. 4), ++ indicates saturated bands, + indicates bands that are not saturated, +/- represents weak bands. Indications on transduced USSC populations are based on cells counts of strong fluorescent cells in relation to DAPI stained nuclei following immunocytochemical analysis. In H1-F-H4-USSC cultures 12 % of strongly AAT positive cells were detected. In cultures of F-H4-USSC less than 0.5 % of cells were strongly positive for AAT.
[0027] Figure 8 depicts the expression of hepatocyte transcription factors by transduced USSC. RT-PCR analysis of endogenous transcription factors was carried out on USSC transduced with HNFla, FOXA2, HNF4a and HNF6 (H1-F-H4-H6-USSC). cDNA of human hepatocyets and pooled vectors (each 1 pg of plasmid) were used as positive controls.
[0028] Figure 9 shows that transduced USSC express human serum albumin (ALB). ALB is detected immunocytochemically in H1-F-H4-H6-USSC before (dayO) and after differentiation (dayl2). In contrast in Mock-transduced USSC (pUC2-USSC) a weak ALB expression represented in some cells is detectable before and after differentiation (dayO and dayl2 respectively). Rhodamine-conjugated antibodies were used to detect human serum albumin; DNA was detected by DAPI-staining. (HI : transduction with HNFla; F: transduction with FOXA2; H4: transduction with HNF4a; H6: transduction with HNF6; magnification of the lens: 20X) [0029] Figure 10 demonstrates, that a-fetoprotein (AFP) is neither expressed in Mock- transduced USSC (pUC2-USSC) nor in H1-F-H4-H6-USSC before (dayO) and after differentiation (dayl2). Fluorescein isothiocyanate (FITC)-conjugated antibodies were used to detect human a-fetoprotein; DNA was detected by DAPI-staining. (HI : transduction with HNFla; F: transduction with FOXA2; H4: transduction with HNF4a; H6: transduction with HNF6; magnification of the lens: 20X)
[0030] Figure 11 shows the sequences of primers used in the generation of data shown in the preceding Figures. SEQ ID NOs are indicated in parentheses.
[0031] Figure 12 demonstrates performance of hepatocyte functions by H1-F-H4-H6- USSC. Albumin secretion and urea production were calculated by referring concentrations in supernatants to durance of medium condition and total protein amount of analyzed cells. Induction of CYP3 A4 activity was analyzed by addition of rifampicin in to culture medium for 48 hours before measurements, (d: day, h: hour, RLU: relative light units, RIF: rifampicin). A: Albumin secretion of H1-F-H4-H6-USSC measured by enzyme-linked immunosorbent assay (ELISA). (n = 3 individual populations; data demonstrate mean ± SD) B: Urea production of iH-USSC measured by a colorimetric assay, (n = 3 individual populations; data demonstrate mean ± SD) C: CYP3A4 activity of H1-F-H4-H6-USSC was determined by a luminogenic assay. Hep G2 indicates the respective human hepatocellular carcinoma cell line. Data are indicated as mean ± SD from 4 individual cell populations.
[0032] A method of generating a cell of hepatocyte phenotype according to the invention can be taken to define a method of forward programming an adherent adult multipotent cell. Forward programming refers to an alteration in the differentiation status of a cell, typically by increasing expression of one or more lineage-determining genes in the multipotent cell. Forward programming may differ from directed differentiation, where an increased expression of endogenous genes is induced by adding growth factors or certain low molecular weight molecules to the culture medium. The growth factors or low molecular weight molecules signal though cell surface proteins and surface protein-mediated signalling to activate endogenous pathways toward the lineage desired. In forward programming, expression of programming factors usually found only intra-cellularly are increased by introducing or inducing the gene expression cassette or by being added directly, for example in the form of polypeptides or RNA molecules. As a result, programming factor genes for differentiation are activated directly, thereby by-passing the cell surface proteins and surface protein-mediated signalling pathways. In this regard, the word "programming" refers to a process that changes a cell to form progeny of at least one cell type different from the original cell and, either in culture or in vivo, different from it would have under the same conditions without programming. This means that after sufficient proliferation, a measurable proportion of progeny having phenotypic characteristics of the new cell type if essentially no such progeny could form before programming.
[0033] In some embodiments a method of the invention is a method of differentiating adherent adult multipotent cells. "Differentiation" is a process known to those skilled in the art by which a less specialized cell becomes a more specialized cell type. The question of how adult non-hepatic stem cells are converted into hep atocyte- like cells in vivo is so far unsettled. Originally it was assumed that the so called plasticity of cells allows differentiation into hepatocyets. This possibility is, however, controversial since the publication of fusion incidents of transplanted stem cells with recipient cells (Vassilopoulos, G, et al, Nature (2003) 422, 901-904; Kashofer, K, et al, Stem Cells (2006) 24, 1104-1112). The discovery of the present inventors, on which the present invention is based, that increasing the amounts of HNF-6 and HNF-Ια is sufficient to cause differentiation into hepatocyte-like cells is thus surprising.
[0034] A method of the present invention provides one or more cells of a hepatic phenotype, namely of hepatocyte phenotype. Such cells may also be addressed as hepatocyte- like cells. The term phenotype is understood in the art to refer to detectable characteristics of a cell or organism. These characteristics in particular include the morphology, the development, the biochemical and/or physiological properties, phenology, and behaviour. The phenotype thus includes inter alia the molecules, such as proteins that are present within and on the surface of a cell. The term phenotype is typically contrasted to the genotype, which refers to heredity. The characteristics defining the phenotype are the manifestation of gene expression.
[0035] A hepatocyte is a cell of a cell type that makes up 70-80% of the cytoplasmic mass of the liver. Hepatocytes are involved in protein synthesis, protein storage, transformation of carbohydrates, synthesis of cholesterol, bile salts and phospholipids, and the detoxification, modification and excretion of exogenous and endogenous substances. Hepatocytes generate serum albumin, fibrinogen, and the prothrombin group of clotting factors. A hepatocyte also initiates the formation and secretion of bile. Hepatocytes are also the main site for the synthesis of lipoproteins, ceruloplasmin, transferrin, complement and glycolproteins. In addition, hepatocytes have the ability to metabolize, detoxify, and inactivate exogenous compounds such as drugs and insecticides, and endogenous compounds such as steroids. [0036] Characteristics of a hepatocyte phenotype include the expression of cell markers, enzymatic activity, and the characterization of morphological features and intercellular signalling. Where for example a plurality of characteristics of hepatocytes is present in a single cell, the cell may be regarded as being of hepatocyte phenotype. Morphological features characteristic of hepatocytes that may be assessed, include a polygonal cell shape, a binucleate phenotype, the presence of rough endoplasmic reticulum for synthesis of secreted protein, the presence of Golgi-endoplasmic reticulum lysosome complex for intracellular protein sorting, the presence of peroxisomes and glycogen granules, relatively abundant mitochondria, and the ability to form tight intercellular junctions resulting in creation of bile canalicular spaces.
[0037] Characteristics of a hepatocyte phenotype may also be assessed on the basis of the presence of phenotypic markers (see below), i.e. particular molecules and/or moieties of molecules found in or on the cell, typically on the cell surface. Assessment of the level of expression of markers can be determined in comparison to a reference to other cells. As positive controls for the markers of mature hepatocytes there may be used for instance adult hepatocytes of the species of interest may be used. Negative controls may for example include cells of a different lineage, such as lymphocytes or fibroblasts. Protein and oligosaccharide determinants characteristic of a hepatocyte phenotype may be detected using any known methodology available, such as immunological techniques, e.g. flow immunocytochemistry in the case of a cell surface marker, immunohistochemistry in the case of an intracellular or a cell surface marker. Further suitable techniques include Western blot analysis, for instance of a cellular extract, an enzyme-linked immunoassay, a radioimmunoassay or a fluorescence titration assay, which may for example be carried out on a cellular extract or a medium in which the cells are being cultured. A radioimmunoassay (RIA) is based on the measurement of radioactivity associated with a complex formed between an antibody or a proteinaceous binding molecule with antibody-like functions and an antigen, while an ELISA is based on the measurement of an enzymatic reaction associated with a complex formed between an antibody or a proteinaceous binding molecule with antibody-like functions and an antigen.
[0038] An immunological technique relies on the use of antibodies or binding molecules with antibody-like functions, typically being proteinaceous binding molecules. An antibody is an immunoglobulin or a fragment thereof. Examples of (recombinent) immunoglobulin fragments are Fab fragments, Fv fragments, single-chain Fv fragments (scFv), diabodies, triabodies (Iliades, P., et al, FEBS Lett (1997) 409, 437-441), decabodies (Stone, E., et al, Journal of Immunological Methods (2007) 318, 88-94) and other domain antibodies (Holt, L.J., et al, Trends Biotechnol. (2003), 21, 11, 484-490). An example of a proteinaceous binding molecule with antibody-like functions is a mutein based on a polypeptide of the lipocalin family (WO 2003/029462; WO 2005/019254; WO 2005/019255; WO 2005/019256; Beste et al, Proc. Natl. Acad. Sci. USA (1999) 96, 1898-1903). Lipocalins, such as the bilin binding protein, the human neutrophil gelatinase-associated lipocalin, human Apo lipoprotein D, human tear lipocalin, or glycodelin, posses natural ligand-binding sites that can be modified so that they bind to selected small protein regions known as haptens. Other non-limiting examples of further proteinaceous binding molecules include, but are not limited to, the so-called glubodies (see WO 96/23879), proteins based on the ankyrin scaffold (Mosavi, L.K., et al, Protein Science (2004) 13, 6, 1435-1448) or the crystalline scaffold (WO 2001/04144), the proteins described by Skerra (J. Mol. Recognit. (2000) 13, 167-187), AdNectins, tetranectins, avimers and peptoids. Avimers contain so called A-domains that occur as strings of multiple domains in several cell surface receptors (Silverman, J, et al, Nature Biotechnology (2005) 23, 1556-1561). Adnectins, derived from a domain of human fibro- nectin, contain three loops that can be engineered for immunoglobulin-like binding to targets (Gill, D.S. & Damle, N.K., Current Opinion in Biotechnology (2006) 17, 653-658). Tetranectins, derived from the respective human homotrimeric protein, likewise contain loop regions in a C-type lectin domain that can be engineered for desired binding (ibid.). Peptoids, which can act as protein ligands, are oligo(N-alkyl) glycines that differ from peptides in that the side chain is connected to the amide nitrogen rather than the a carbon atom. Peptoids are typically resistant to proteases and other modifying enzymes and can have a much higher cell permeability than peptides (see e.g. Kwon, Y.-U., and Kodadek, T., J. Am. Chem. Soc. (2007) 129, 1508-1509).
[0039] In a detecting the presence of phenotypic markers an antibody or a molecule with antibody-like functions may be used that is linked to an attached label, such as for instance in Western analysis or ELISA. Where desired, an intracellular immunoglobulin may be used for detection. Some or all of the steps of detection may be part of an automated detection system. Illustrative examples of such systems are automated real-time PCR platforms, automated nucleic acid isolation platforms, PCR product analysers and real-time detection systems.
[0040] A further technique that can also be carried out to detect the presence of phenotypic markers is Fluorescence Microscopy, including Ratio Fluorescence Microscopy. In ratio fluorescence microscopy two fluorescence images are collected and the parameter of interest is quantified as a ratio of the fluorescence in one image to that in the other image. A further technique suitable for detecting the presence of phenotypic markers on the surface of cells is fluorescence resonance energy transfer (FRET). In FRET an excited fluorescent donor molecule, rather than emitting light, transfers that energy via a dipole-dipole interaction to an acceptor molecule in close proximity. If the acceptor is fluorescent, then the decrease in donor fluorescence due to FRET is accompanied by an increase in acceptor fluorescence (i.e., for example, sensitized emission). The amount of FRET depends strongly on distance, typically decreasing as the sixth power of the distance, so that fluorophores can directly report on phenomena occurring on the scale of a few nanometers, well below the resolution of optical microscopes. Among other purposes, FRET has been used to map distances and study aggregation states, membrane dynamics, or DNA hybridization.
[0041] A further characteristic of a hepatocyte phenotype that may be assessed is bile secretion. Detection of biliary secretion may for instance be done using the so called fluorescein diacetate time lapse assay. In this technique the cells of interest are incubated with doxycycline and fluorescein diacetate, a non- fluorescent precursor of fluorescein. Uptake and metabolization to fluorescein is then determined. As two further characteristic of a hepatocyte phenotype, glycogen synthesis and the cell's ability to store glycogen may be determined.
[0042] In a method according to the present invention adherent adult multipotent cells are used. A cell is termed multipotent if it has the potential to give rise to cells from multiple, but a limited number of lineages of an organism. Examples of multipotent cells include, but are not limited to, stem cells and progenitor cells. In contrast thereto, a "totipotent" cell is a cell with the potential to differentiate into any type of somatic or germ cell found in the organism. Thus, any desired cell may be derived, by some means, from a totipotent cell. Finally, unipotent cells can produce only one cell type. Any of the terms unipotent, multipotent and totipotent generally refer to an undifferentiated cell or a partially differentiated cell. Examples of an undifferentiated cell include, but are not limited to, a stem cell, e.g. an embryonic stem cell, including a mammalian embryonic stem cell, such as a human, a mouse, a rat or a Guinea pig embryonic stem cell, any of which may also be a cell of an embryonic stem cell line. A stem cell may also be a trophoblast stem cell or any extraembryonic stem cell, e.g. an adult stem cell, also called a somatic stem cell. Further examples of an undifferentiated cell include a germ cell, an oocyte, a blastomer, and an inner cell mass cell. In some embodiments the adult multipotent cells have been obtained from a host organism such as a fish, an amphibian, a bird or a mammal.
[0043] In some embodiments of the present invention the adherent adult multipotent cell is a stem cell. In one embodiment the stem cell is a somatic stem cell. Somatic stem cells have been identified in most organ tissues. In one embodiment a somatic stem cell is a hemato- poietic stem cell, which is a mesoderm-derived cell that can be purified based on cell surface markers and functional characteristics. The hematopoietic stem cell, isolated from bone marrow, blood, cord blood, fetal liver and yolk sac, is the progenitor cell that reinitiates hematopoiesis for the life of a recipient and generates multiple hematopoietic lineages. When transplanted into lethally irradiated animals or humans, hematopoietic stem cells can repopulate the erythroid, neutrophil-macrophage, megakaryocyte and lymphoid hematopoietic cell pool. In vitro, hematopoietic stem cells can be induced to undergo at least some self-renewing cell divisions and can be induced to differentiate to the same lineages as is seen in vivo.
[0044] In one embodiment the stem cell is a cord blood stem cell such as a mesenchymal stem cell (MSC) or an unrestricted somatic stem cell (USSC). A mesenchymal stem cell may also be of umbilical cord tissue or of entirely different origin, such as adipose tissue, muscle tissue, placenta tissue or the dental pulp of deciduous baby teeth. A mesenchymal stem cell has cell surface molecules such as CD73, CD90 and CD 105 that are typical mesenchymal cell surface proteins. A mesenchymal stem cell also has fibroblastoid morphology and shows adherent growth on plastic surfaces. A mesenchymal stem cell, originally derived from the embryonic mesoderm and isolated from adult bone marrow, is known to be able to differentiate to form muscle, bone, cartilage, fat, marrow stroma or tendon. In some embodiments the stem cell may be one of a gastrointestinal stem cell, an epidermal stem cell, a neural stem cell or a hepatic stem cell, also termed oval cell. In some embodiments the stem cells has been isolated from umbilical cord, placenta, amniotic fluid, chorion villi, blastocysts, bone marrow, adipose tissue, brain, peripheral blood, the gastrointestinal tract, cord blood, blood vessels, skeletal muscle, skin, liver or menstrual blood.
[0045] An example of a cell that is a partially differentiated cell is a progenitor cell. A progenitor cell, which may be unipotent or multipotent, has a capacity to differentiate into a specific type of cell and a limited ability of self-renewal, which it cannot maintain. Further examples of a partially differentiated cell include, but are not limited to, a precursor cell, i.e. a stem cell that has developed to the stage where it is committed to forming a particular kind of new cell, a lineage-restricted stem cell, and a somatic stem cell.
[0046] The cell may be obtained or derived from any host organism. The cell may be directly taken from a respective host organism in form of a sample such as e.g. a biopsy or a blood sample. It may also have been derived from a host organism and subsequently been cultured, grown, transformed or exposed to a selected treatment. The host organism from which the cell is derived or obtained may be any organism such as a microorganism, an animal, such as a fish, an amphibian, a reptile, a bird, a mammal, including a rodent species, an invertebrate species, e.g. of the subclass Lissamphibia that includes e.g. frogs, toads, salamanders or newts, or a plant. Examples of mammals include, but are not limited to, a rat, a mouse, a rabbit, a guinea pig, a squirrel, a hamster, a vole, a platypus, a dog, a goat, a horse, a pig, an elephant, a chicken, a macaque, a chimpanzee and a human.
[0047] In some embodiments the method of the invention includes assessing the absence of undifferentiated cells or cells not entirely differentiated, for example by using an antibody that specifically binds to a polypeptide cell surface marker present in undifferentiated cells but not in cells of hepatocyte phenotype. In some embodiments the protein or polypeptide cell surface marker present on the surface of undifferentiated cells but not in cells of hepatocyte phenotype is at least one of CXCR4, CD10, CD13, CD41a (gpllbllla), CD34, CD56, CD90, CDl lO, CD117, CD123, CD133, CD135, CD277 and CD318, at least one of CD10, CD13, CD56, and an MHC Class-I cell surface antigen, and/or at least one of CD3, CD5, CD7, CDl lb, CD14, CD15, CD16, CD19, CD25, CD45, and CD65.
[0048] In some embodiments the method of the invention includes isolating and/or identifying cells of hepatocyte phenotype by positive or negative selection using an antibody or a proteinaceous binding molecule with antibody-like functions, as indicated above. The cells can for instance be identified and/or isolated by fluorescent activated cell sorting (FACS) or affinity column chromatography. The cells can also be identified on the basis of identifying plasma membrane proteins by mass spectrometry or other suitable techniques.
[0049] Where the method of the invention is intended to be used for a progenitor cell, i.e. a cell giving rise to a mature somatic cell, any progenitor cell may be used in this method of the invention. Examples of suitable progenitor cells include, but are not limited to, neuronal progenitor cells, endothelial progenitor cells, erythroid progenitor cells, cardiac progenitor cells, oligodendrocyte progenitor cells, retinal progenitor cells, or hematopoietic progenitor cells.
[0050] In a method according to the present invention the amount of two or more transcription factors in the respective cell is increased. The amount, which may also be referred to as the level of the respective protein, indicates the absolute number of molecules of the transcription factors in the cell.
[0051] A method according to the invention includes increasing the cellular amount of the transcription factor hepatocyte nuclear factor 6 (HNF-6), also called one cut domain family member 1 (OC-1) or one cut homeobox 1. The protein HNF-6 may be any respective variant or isoform of the respective species, e.g. human. The protein may for example be the human protein of the Swissprot/Uniprot accession number Q9UBC0 (version 107 as of 18 April 2012, SEQ ID NO: 59), the murine protein of the Swissprot/Uniprot accession number 008755 (version 113 as of 18 April 2012, SEQ ID NO: 60), the rat protein of the Swissprot/Uniprot accession number P70512 (version 93 as of 18 April 2012, SEQ ID NO: 61), the bovine protein represented by the fragment of the Swissprot/Uniprot accession number Q5DM44 (version 41 as of 21 March 2012, SEQ ID NO: 62), the protein of the rhesus macaque (Macaca mulatta) of the Swissprot/Uniprot accession number G7MXH6 (version 2 as of 21 March 2012, SEQ ID NO: 63) or the protein of the crab-eating macaque (Cynomolgus monkey, Macaca fascicularis) of the Swissprot/ Uniprot accession number G7PBI4 (version 2 as of 21 March 2012, SEQ ID NO: 64).
[0052] A natural variant of the human FINF-6 protein is named VAR 010729 in the data base entry of Swissprot/Uniprot accession number Q9UBC0, having an alanine instead of a proline at position 75 of the amino acid sequence. The sequence of the rat FINF-6 protein depicted as the canonical sequence in the data base entry of Swissprot/Uniprot accession number P70512 has the identifier P70512-1 and is also called the isoform alpha. A further isoform, called the isoform beta, has the identifier P70512-2, also named VSP 002312, in this data base entry. It differs from isoform alpha in that it has the sequence Ala Glu Ser Ala Met Gly Gly Ser Val Pro Ser Leu Arg He Thr Ser Gly Gly Pro Gin Leu Ser Val Pro Pro Leu Pro instead of an alanine at position 368 of the sequence defining Swissprot/Uniprot accession number P70512-1.
[0053] FINF-6 may be the protein encoded by the ONECUT1 (one cut homeobox 1) gene, also called FTNF6, HNF-6 or HNF6A, for example the human gene of GenBank Gene ID No 3175 as of 06 May 2012, the mouse gene of GenBank Gene ID No 15379 as of 20 April 2012, the rat gene of GenBank Gene ID No 25231 as of 20 April 2012 or the bovine gene of GenBank Gene ID No 503584 as of 10 May 2012.
[0054] A further transcription factor, the cellular amount of which is increased in a method according to the invention, is the transcription factor hepatocyte nuclear factor la (FTNF-la), also called liver-specific transcription factor LF-B1 or sometimes simply transcription factor 1 (TCF-1). The protein FiNF-la may be any respective variant or isoform of the respective species, e.g. human. In some embodiments FiNF-la is the human protein of the Swissprot/ Uniprot accession number P20823 (version 157 as of 18 April 2012, SEQ ID NO: 65), the mouse protein of the Swissprot/Uniprot accession number P22361 (version 126 as of 18 April 2012, SEQ ID NO: 66), the rat protein of the Swissprot/Uniprot accession number P15257 (version 129 as of 18 April 2012, SEQ ID NO: 67), the chicken protein of the Swissprot/Uniprot accession number Q90867 (version 92 as of 13 June 2012, SEQ ID NO: 68) or the salmon (Salmo salar) protein of the Swissprot/Uniprot accession number Q91474 (version 77 as of 18 April 2012, SEQ ID NO: 69).
[0055] The sequence of the human FiNF-la depicted as the canonical sequence in the data base entry of Swissprot/Uniprot accession number P20823 has the identifier P20823-1 and is also called the isoform A. Two further isoforms, called isoforms B and C, have the identifiers P20823-2 and P20823-3 in this data base entry. Isoform B differs from isoform A firstly in that it has the sequence Gly Glu His Pro Val Pro His Thr Ala Gly ... Ala Cys Val Ser Gly Thr Ser Val Phe Pro instead of the sequence Ala Leu Tyr Ser His Lys Pro Glu Val Ala ... Leu Ala Ser Leu Thr Pro Thr Lys Gin Val at positions 501 to 542 of the amino acid sequence. Secondly, Isoform B differs from isoform A in that it does not contain the amino acids 543 to 601 of the amino acid sequence. Isoform C firstly differs from isoform A in that it has the sequence Lys Leu Val Gly Met Gly Gly His Leu Gly ... Ser His Cys Ala Thr Ser Val He Pro Gly instead of the sequence Leu Ala Ser Thr Gin Ala Gin Ser Val Pro ... Thr Gin Ser Pro Phe Met Ala Thr Met Ala at positions 438 to 494 of the amino acid sequence. Secondly, Isoform C differs from isoform A in that it does not contain the amino acids 495 to 601 of the amino acid sequence present in isoform A.
[0056] HNF-la may be the protein encoded by the FINF1A gene, for example the human gene of GenBank Gene ID No 6927 as of 06 May 2012, the mouse gene of GenBank Gene ID No 21405 as of 06 May 2012, the rat gene of GenBank Gene ID No 24817 as of 20 April 2012, the chicken gene of GenBank Gene ID No 416967as of 17 March 2012 or the Xenopus laevis gene of GenBank Gene ID No 378589 as of 12 November 2012.
[0057] In some embodiments of a method according to the invention the cellular amount of the hepatocyte nuclear factor 4a (FTNF-4a) is being increased, which is also called nuclear receptor subfamily 2 group A member 1 (NR2A1) or sometimes simply transcription factor 14 (TCF-14). The protein FTNF-4a may be any respective variant or isoform of the respective species, e.g. human. The protein may for example be the human protein of the Swissprot/Uniprot accession number P41235 (version 147 as of 18 April 2012, SEQ ID NO: 75), the mouse protein of the Swissprot/Uniprot accession number P49698 (version 117 as of 18 April 2012, SEQ ID NO: 76), the rat protein of the Swissprot/Uniprot accession number P22449 (version 123 as of 18 April 2012, SEQ ID NO: 77) or the Xenopus laevis protein of the Swissprot/Uniprot accession number Q91766 (version 90 as of 18 April 2012, SEQ ID NO: 78).
[0058] The sequence of the human FINF-4a depicted as the canonical sequence in the data base entry of Swissprot/Uniprot accession number P41235 has the identifier P41235-1 and is also called FINF-4al or the isoform FINF4-B. Six further isoforms, called isoforms HNF-4a2 or HNF-4A, HNF-4a3 or HNF-4C, HNF-4a4, HNF-4a7, HNF-4a8 and HNF-4a9 have the identifiers P41235-2, P41235-3, P41235-4, P41235-5, P41235-6 and P41235-7 in this data base entry. FINF-4a2 differs from FINF-4al in that it has only a single serine instead of the sequence Cys Glu Trp Pro Arg Pro Arg Gly Gin Ala Ala at positions 418 to 428 of the amino acid sequence. FINF-4a3 differs from FINF-4al in that it has the sequence Pro Cys Gin Ala Gin Glu Gly Arg Gly Trp ... Ser Pro Leu Cys Arg Phe Gly Gin Val Ala instead of the sequence Ser Pro Ser Asp Ala Pro His Ala His His ... Gin Pro Thr He Thr Lys Gin Glu Val He at positions 378 to 474 of the amino acid sequence. HNF-4a4 differs from HNF-4al in that it contains the sequence Asn Asp Leu Leu Pro Leu Arg Leu Ala Arg Leu Arg His Pro Leu Arg His His Trp Ser He Ser Gly Gly Val Asp Ser Ser Pro Gin Gly instead of the asparagine at position 38 of the amino acid sequence. HNF-4a7 differs from HNF-4al in that it has the N- terminal sequence Met Val Ser Val Asn Ala Pro Leu Gly Ala Pro Val Glu Ser Ser Tyr instead of the sequence Met Arg Leu Ser Lys Thr Leu Val Asp Met Asp Met Ala Asp Tyr Ser Ala Ala Leu Asp Pro Ala Tyr Thr Thr Leu Glu Phe Glu Asn Val Gin Val Leu Thr Met Gly Asn at positions 1 to 38 of the amino acid sequence. HNF-4a8 differs from HNF-4al firstly in that it has the N-terminal sequence Met Val Ser Val Asn Ala Pro Leu Gly Ala Pro Val Glu Ser Ser Tyr instead of the sequence Met Arg Leu Ser Lys Thr Leu Val Asp Met Asp Met Ala Asp Tyr Ser Ala Ala Leu Asp Pro Ala Tyr Thr Thr Leu Glu Phe Glu Asn Val Gin Val Leu Thr Met Gly Asn at positions 1 to 38 of the amino acid sequence. Secondly, HNF-4a8 differs from HNF- 4a 1 in that it contains only a serine instead of the sequence Cys Glu Trp Pro Arg Pro Arg Gly Gin Ala Ala at the sequence positions 418 to 428 of the amino acid sequence. HNF-4a9 differs from HNF-4al firstly in that it has the N-terminal sequence Met Val Ser Val Asn Ala Pro Leu Gly Ala Pro Val Glu Ser Ser Tyr instead of the sequence Met Arg Leu Ser Lys Thr Leu Val Asp Met Asp Met Ala Asp Tyr Ser Ala Ala Leu Asp Pro Ala Tyr Thr Thr Leu Glu Phe Glu Asn Val Gin Val Leu Thr Met Gly Asn at positions 1 to 38 of the amino acid sequence. Secondly, HNF-4a9 differs from HNF-4al in that it has the sequence Pro Cys Gin Ala Gin Glu Gly ArgGly Trp ... Ser Pro Leu Cys Arg Phe Gly Gin Val Ala instead of the sequence Ser Pro Ser Asp Ala Pro His Ala His His ... Gin Pro Thr He Thr Lys Gin Glu Val He at positions 378 to 474 of the amino acid sequence.
[0059] The sequence of the mouse HNF-4a depicted as the canonical sequence in the data base entry of Swissprot/Uniprot accession number P49698 has the identifier P49698-1 and is also called the long isoform. The short isoform with the identifier P49698-2 differs from the long isoform in that it has a serine instead of the sequence Cys Glu Trp Pro Arg Pro Arg Gly Gin Ala Ala at positions 418 to 428 of the amino acid sequence.
[0060] HNF-4a is in some embodiments the protein encoded by the HNF4A gene, for example the human gene of GenBank Gene ID No 3172 as of 06 May 2012, the mouse gene of GenBank Gene ID No 15378 as of 06 May 2012, the rat gene of GenBank Gene ID No 25735 as of 06 May 2012, the bovine gene of GenBank Gene ID No 25735 as of 06 May 2012 or the horse gene of GenBank Gene ID No 100056007 as of 16 November 2011.
[0061] A further transcription factor, the cellular amount of which is increased in some embodiments of a method according to the invention, is the transcription factor hepatocyte nuclear factor 3β (HNF-3 ), also called Forkhead box protein A2 (FOXA2) or sometimes transcription factor 3B (TCF-3B). The protein HNF-3 may be any respective variant or isoform of the respective species, e.g. human. The protein may for example be the human protein of the Swissprot/Uniprot accession number Q9Y261 (version 120 as of 18 April 2012, SEQ ID NO: 70), the mouse protein of the Swissprot/Uniprot accession number P35583 (version 112 as of 18 April 2012, SEQ ID NO: 71), the rat protein of the Swissprot/Uniprot accession number P32182 (version 104 as of 18 April 2012, SEQ ID NO: 72), the protein of Medaka fish (Japanese ricefish, Oryzias latipes) of the Swissprot/Uniprot accession number 042097 (version 79 as of 18 April 2012, SEQ ID NO: 73) or the chicken protein of the Swissprot/ Uniprot accession number Q9PWP8 (version 76 as of 18 April 2012, SEQ ID NO: 74).
[0062] The sequence of the human HNF-3 protein depicted as the canonical sequence in the data base entry of Swissprot/Uniprot accession number Q9Y261 has the identifier Q9Y261-1 and is also called isoform 1. A further isoform, isoform 2, has the identifier Q9Y261-2 in this data base entry. It differs from isoform 1 in that it has the sequence Met His Ser Ala Ser Ser Met instead of the N-terminal (i.e., position 1) methionine of the amino acid sequence of Swissprot/Uniprot accession number Q9Y261-1.
[0063] HNF-3 may be the protein encoded by the HNF3B gene, also called the foxa2 gene, for example the human gene of GenBank Gene ID No 15376 as of 20 April 2012, the zebra fish gene of GenBank Gene ID No 30126 as of 29 April 2012, the mouse gene of GenBank Gene ID No 15376 as of 20 April 2012, the rat gene of GenBank Gene ID No 25099 as of 20 April 2012 or the Xenopus laevis gene of GenBank Gene ID No 100127318 as of 24 December 2011.
[0064] A variant of any of the above transcription factors includes a protein with a high sequence identity to a respective known form of the transcription factor. A corresponding sequence of a variant that has a high sequence identity to a known form of the protein has in some embodiments at least 65 %, at least 70 %, at least 75 %, at least 80 %, at least 82 %, at least 85 %, at least 87 %, at least 90% identity, including at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 99.5% identity to the sequence of the known form of the protein. By "identity" is meant a property of sequences that measures the similarity or relationship of the variant and the corresponding known protein. Identity is measured by dividing the number of identical residues by the total number of residues and multiplying the product by 100. Those skilled in the art will be aware of the fact that several computer programs are available for determining sequence identity using standard parameters, for example Blast (Altschul, et al. (1997) Nucleic Acids Res. 25, 3389-3402), Blast2 (Altschul, et al. (1990) J. Mol. Biol. 215, 403-410), and Smith- Waterman (Smith, et al. (1981) J. Mol. Biol. 147, 195-197). A variant of a known protein may include one or more mutations - relative to the sequence of the known protein form. A respective variant may in some embodiments have been obtained from the sequence of a known protein form by molecular biology techniques, including recombinant techniques.
[0065] In some embodiments a variant has a sequence that contains a substitution (or replacement) that is a conservative substitution, not being associated with a change in biological activity. Nevertheless, any substitution - including non-conservative substitution or one or more from the exemplary substitutions listed below - is envisaged as long as the variant retains its capability of acting as a transcription factor with the same specificity as the known form of the protein, respectively, and/or it has an identity to the then substituted sequence in that it is at least 60%>, such as at least 65%>, at least 70%>, at least 75%>, at least 80%>, at least 85 % or higher identical to the "original" sequence.
[0066] Conservative substitutions are generally the following substitutions, listed according to the amino acid to be mutated, each followed by one or more replacement(s) that can be taken to be conservative: Ala— Gly, Ser, Val; Arg— Lys; Asn— Gin, His; Asp— Glu; Cys→ Ser; Gin→ Asn; Glu→ Asp; Gly→ Ala; His→ Arg, Asn, Gin; He→ Leu, Val; Leu→ He, Val; Lys→ Arg, Gin, Glu; Met→ Leu, Tyr, He; Phe→ Met, Leu, Tyr; Ser→ Thr; Thr— Ser; Trp— Tyr; Tyr— Trp, Phe; Val— He, Leu. Other substitutions are also permissible and can be determined empirically or in accord with other known conservative or non-conservative substitutions. As a further orientation, the following eight groups each contain amino acids that can typically be taken to define conservative substitutions for one another:
1) Alanine (Ala), Glycine (Gly);
2) Aspartic acid (Asp), Glutamic acid (Glu);
3) Asparagine (Asn), Glutamine (Gin);
4) Arginine (Arg), Lysine (Lys);
5) Isoleucine (He), Leucine (Leu), Methionine (Met), Valine (Val);
6) Phenylalanine (Phe), Tyrosine (Tyr), Tryptophan (Trp);
7) Serine (Ser), Threonine (Thr); and
8) Cysteine (Cys), Methionine (Met)
[0067] In contrast thereto, the following substitutions can be expected to increase the likelihood of a change in biological activity, representing more substantial changes: Ala— Leu, He; Arg→ Gin; Asn→ Asp, Lys, Arg, His; Asp→ Asn; Cys→ Ala; Gin→ Glu; Glu→ Gin; His→ Lys; He→ Met, Ala, Phe; Leu→ Ala, Met, Norleucine; Lys→ Asn; Met→ Phe; Phe→ Val, He, Ala; Trp→ Phe; Tyr→ Thr, Ser; Val→ Met, Phe, Ala.
[0068] In a method according to the invention, the amount of at least two transcription factors is increased, as already explained above. Increasing the amount/level of a transcription factor in a cell according to the invention may be achieved by increasing the formation and/or by reducing the degradation of the transcription factor in the cell. Increasing the formation of a transcription may be achieved by activating and/ or enhancing one or more homologous, i.e. endogenous, genes encoding the transcription factor. Increasing the formation of a transcription may also be achieved by increasing the expression of a homologous, but transcriptionally repressed transcription factor, by reversing the silencing or inhibitory effect on the expression of a transcription factor gene, for example by regulating the upstream transcription factor expression or epigenetic modulation. In some embodiments the method of the invention includes introducing into the cell a nucleic acid molecule, typically a heterologous nucleic acid molecule, encoding the respective transcription factor, capable of allowing expression of the same in the cell. The method in such embodiments further includes expressing the heterologous transcription factor.
[0069] The term "nucleic acid molecule" as used herein refers to any nucleic acid in any possible configuration, such as single stranded, double stranded or a combination thereof. Nucleic acids include for instance DNA molecules, RNA molecules, analogues of the DNA or RNA generated using nucleotide analogues or using nucleic acid chemistry, locked nucleic acid molecules (LNA), protein nucleic acids molecules (PNA), alkylphosphonate and alkylphosphotriester nucleic acid molecules and tecto-RNA molecules (e.g. Liu, B., et al, J. Am. Chem. Soc. (2004) 126, 4076-4077). DNA or RNA may be of genomic or synthetic origin and may be single or double stranded. Such nucleic acid can be e.g. mRNA, cRNA, synthetic RNA, genomic DNA, cDNA synthetic DNA, a copolymer of DNA and RNA, oligonucleotides, etc. A respective nucleic acid may furthermore contain non-natural nucleotide analogues and/or be linked to an affinity tag or a label. A PNA molecule is a nucleic acid molecule in which the backbone is a pseudopeptide rather than a sugar. Accordingly, PNA generally has a charge neutral backbone, in contrast to DNA or RNA. Nevertheless, PNA is capable of hybridising at least complementary and substantially complementary nucleic acid strands, just as e.g. DNA or RNA (to which PNA is considered a structural mimic). LNA has a modified RNA backbone with a methylene bridge between C4' and 02', providing the respective molecule with a higher duplex stability and nuclease resistance. Alkylphosphonate and alkylphosphotriester nucleic acid molecules can be viewed as a DNA or an RNA molecule, in which phosphate groups of the nucleic acid backbone are neutralized by exchanging the P-OH groups of the phosphate groups in the nucleic acid backbone to an alkyl and to an alkoxy group, respectively. DNA or RNA may be of genomic or synthetic origin and may be single or double stranded. Such nucleic acid can be e.g. mRNA, cRNA, synthetic RNA, genomic DNA, cDNA synthetic DNA, a copolymer of DNA and RNA, oligonucleotides, etc. A respective nucleic acid may furthermore contain non-natural nucleotide analogues and/or be linked to an affinity tag or a label.
[0070] Many nucleotide analogues are known and can be used in nucleic acids used in a method of the invention, for example as a heterologous nucleic acid introduced into a cell. A nucleotide analogue is a nucleotide containing a modification at for instance the base, sugar, or phosphate moieties. As an illustrative example, a substitution of 2'-OH residues of siRNA with 2'F, 2'O-Me or 2Ή residues is known to improve the in vivo stability of the respective RNA. Modifications at the base moiety include natural and synthetic modifications of A, C, G, and T/U, different purine or pyrimidine bases, such as uracil-5-yl, hypoxanthin-9-yl, and 2- aminoadenin-9-yl, as well as non-purine or non-pyrimidine nucleotide bases. Other nucleotide analogues serve as universal bases. Universal bases include 3-nitropyrrole and 5 -nitro indole. Universal bases are able to form a base pair with any other base. Base modifications often can be combined with for example a sugar modification, such as for instance 2'-0-methoxyethyl, e.g. to achieve unique properties such as increased duplex stability.
[0071] As indicated above, a heterologous sequence, e.g. a gene, encoding a transcription factor, such as HNF-Ια or HNF-6, may be introduced into an adherent adult multipotent cell. The sequence, which may be included in a heterologous nucleic acid molecule, may be introduced into the cell by means of recombinant technology. The sequence may be included in any gene delivery system such as for instance a transposon system, a viral gene delivery system, an episomal gene delivery system or a homologous recombination system such as utilizing a zinc finger nuclease, a transcription activator-like effector (TALE) nuclease, or a meganuclease. A heterologous nucleic acid molecule that has a sequence encoding a transcription factor may in some embodiments be included in a vector, typically as a vector carrying a gene of the transcription factor. It may in this regard be advantageous to further use a vector that contains a promoter effective to initiate transcription in the respective host cell (whether of endogenous or heterologous origin). In this regard the present invention also relates to the use of such a nucleic acid molecule, e.g. a respective vector or included therein, for increasing the absolute quantity of a transcription factor in a cell.
[0072] The term "vector", sometimes also referred to as gene delivery system or gene transfer vehicle, relates to a macromolecule or complex of molecules that include(s) a polynucleotide to be delivered to a host cell, whether in vitro, ex vivo or in vivo. Typically a vector is a single or double-stranded circular nucleic acid molecule that allows or facilitates the transfer of a nucleic acid sequence into a cell. A vector can generally be transfected into cells and replicated within or independently of a cell genome. A circular double-stranded nucleic acid molecule can be cut and thereby linearized upon treatment with restriction enzymes. An assortment of nucleic acid vectors, restriction enzymes, and the knowledge of the nucleotide sequences cut by restriction enzymes are readily available to those skilled in the art. A nucleic acid molecule encoding a transcription factor, such as HNF-Ια or FINF-6, can be inserted into a vector by cutting the vector with restriction enzymes and ligating the two pieces together. A vector may for instance be a viral vector, such as a retroviral vector, a Lentiviral vector, a herpes virus based vector or an adenoviral vector. A vector may also be a plasmid vector or a liposome-based extrachromosomal vector, also called episomal vector. Two illustrative examples of an episomal vector are an oriP -based vector and a vector encoding a derivative of EBNA-1. Lymphotrophic herpes virus is a herpes virus which replicates in a lymphoblast and becomes a plasmid for a part of its natural life-cycle. A vector may also be based on an organically modified silicate. In some embodiments a vector may be a transposon-based system, i.e. a transposon/transposase system, such as the so called Sleeping Beauty, the Frog Prince transposon - transposase system or the TTAA-specific transposon piggyBac system. Transposons are mobile genetic elements in that they are sequences of DNA that can move around to different positions within the genome of a single cell, a process called transposition. In the process, a transposon can cause mutations and change the amount of DNA in the genome.
[0073] In some embodiments of a method according to the invention the amount of a transcription factor, e.g. FINF-6 or FINF-Ια, in a cell can be increased by enhancing the expression of homologous FINF-6 and FINF-Ια, respectively. Micro-RNA molecules termed miR-495 and miR-218 target the 3 '-untranslated region of FINF-6 (Simion, A, et al., Biochem Biophys Res Commun. (2010) 391, 1, 293-298), reducing its expression. Such micro-RNA molecules can be silenced, i.e. blocked, by introducing a suitable antagomir, a small RNA molecule of a length of typically 20 to 25 nucleotides, directed against the micro-RNA, into the respective cell (Krutzfeldt, J., et al, Nature (2005) 438, 685-689). Were desired, the expression of a homologous transcription factor, e.g. FINF-6, can also be decreased, for instance where different heterologous FINF-6 is being expressed in a cell. Such reduction of the amount of homologous FINF-6 can for instance be achieved by means of a micro-RNA or small interfering RNA (siRNA) molecule directed against the transcription factor.
[0074] The use of small interfering RNAs, short hairpin and micro RNAs has become a tool to "knock down" specific genes. It makes use of gene silencing or gene suppression through RNA interference (RNAi), which occurs at the posttranscriptional level and involves mRNA degradation. RNA interference represents a cellular mechanism that protects the genome. SiRNA and miRNA molecules mediate the degradation of their complementary RNA by association of the siRNA with a multiple enzyme complex to form what is called the RNA- induced silencing Complex (RISC). The siRNA or miRNA becomes part of RISC and is targeted to the complementary RNA species which is then cleaved. siRNAs are perfectly base paired to the corresponding complementary strand, while miRNA duplexes are imperfectly paired. Activation of RISC leads to the loss of expression of the respective gene (for a brief overview see Zamore, PD, Haley, B Science [2005], 309, 1519-1524). It has been observed that the strongest silencing occurs with sequences that do not form secondary structures (Patzel, V., et al. Nature Biotech. [2005] 23, 1440-1444). Persons skilled in the art thus typically avoid using sequences that for instance are known to form a loop. This can be done by exchanging selected bases to a base that is still able to form a wobble pairing with the target sequence (Patzel, V et al, supra). The siR A/miRNA technique has for example been applied to silencing parasitic DNA sequences, such as the cleavage of HIV RNA, as disclosed in US patent application 2005/0191618.
[0075] A respective siRNA/shRNA/miRNA molecule, as well as a corresponding antagomir (supra), may be directly synthesized or expressed within a cell of interest, for example by means of a vector under the control of an inducible or constitutive promoter. It may also be introduced into a respective cell and/or delivered thereto. One illustrative example of delivering a siRNA, shRNA or miRNA molecule into selected cells in vivo is its non- covalent binding to a fusion protein of a heavy-chain antibody fragment (F) and the nucleic acid binding protein protamin (Song, E. et al, Nature Biotech. (2005), 23, 6, 709-717). Another illustrative example of delivering a siRNA molecule into selected cells in vivo is its encapsulation into a liposome. Morrissey et al. Nature Biotech. (2005), 23, 8, 1002-1007) for instance used a stable nucleic acid-lipid-particle, coated with a polyethylene glycol-lipid conjugate, to form liposomes for intravenous administration. Where it is desired to apply nanoparticles for delivering siRNA or miRNA, a suitable approach of their cell-specific targeting has been described by Weissleder et al. {Nature Biotech. (2005), 23, 11 , 1418-1423). Yet a further example of delivering a siRNA, shRNA or miRNA molecule to a selected target cell is the use of a biological vehicle such as a bacterium or a virus that includes the respective nucleic acid molecule. Xiang et al {Nature Biotech. (2006), 24, 6, 697-702) have for instance used this approach by administering the bacterium E. coli, which transcribed from a plasmid inter alia both shRNA and invasin, thus permitting entry into mammalian cells and subsequent gene silencing therein
[0076] The term "promoter" as used herein, refers to a nucleic acid sequence needed for gene sequence expression. Promoter regions vary from organism to organism, but are well known to persons skilled in the art for different organisms. For example, in prokaryotes, the promoter region contains both the promoter (which directs the initiation of RNA transcription) as well as the DNA sequences which, when transcribed into RNA, will signal synthesis initiation. Such regions will normally include those 5'-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, and the CAAT sequence.
[0077] In a method of the invention a nucleic acid may be introduced into the multipotent cells by any suitable technique of nucleic acid delivery for transformation of a cell available in the art. Examples of suitable techniques include, but are not limited to, direct delivery of DNA, e.g. via transfection, injection, including microinjection, electroporation, calcium phosphate precipitation, by using DEAE-dextran followed by polyethylene glycol, direct sonic loading, liposome mediated transfection, receptor-mediated transfection, microprojectile bombardment, agitation with silicon carbide fibers, Agrobacterium-mediated transformation, desiccation/inhibition-mediated DNA uptake or any combination thereof.
[0078] A method according to the invention may further include measuring the expression of a gene encoding the (heterologous) transcription factor. This can for instance be achieved by determining the number of RNA molecules transcribed from a gene that is under the control of the respective promoter. A method commonly used in the art is the subsequent copy of RNA to cDNA using reverse transcriptase and the coupling of the cDNA molecules to a fluorescent dye. The analysis may for example be performed in form of a DNA microarray. Numerous respective services and kits are commercially available, for instance GeneChip® expression arrays from Affymetrix. Other means of determining gene expression of a transcription factor include, but are not limited to, an oligonucleotide array, and quantitative Real-time Polymerase Chain Reaction (RT-PCR).
[0079] In some embodiments it may be advantageous or desired to calibrate gene expression data or to rate them. Thus, in some embodiments a method according to the invention additionally includes the comparison of obtained results with those of one or more control measurements. Such a control measurement may include any condition that varies from the main measurement itself. It may include conditions of the method under which for example no expression of the respective gene occurs. A further means of a control measurement is the use of a mutated form of a respective gene, for example a gene not encoding the corresponding transcription factor, or encoding a non- functional transcription factor protein.
[0080] A method according to the invention may further include a selection or enrichment step for the cells of hepatocyte phenotype obtained by forward programming or differentiation as described above. To aid selection or enrichment, the adult multipotent cells employed in a method of the invention, such as the pluripotent stem cells or progeny cells thereof, may have a selectable or screenable reporter expression cassette with a reporter gene. By "expression cassette" is meant a combination of the respective gene, including a transcriptional termination sequence, and a suitable transcriptional promoter. In some embodiments the reporter expression cassette may include a hepatocyte-specific transcriptional regulatory element operably linked to a reporter gene. Non-limiting examples of hepatocyte- specific transcriptional regulatory element include a promoter of albumin, a 1 -antitrypsin (AAT), cytochrome p450 3A4 (CYP3A4), apo lipoprotein A-I, or apoE. A mature hepatocyte- specific transcriptional regulatory element may include a promoter of albumin, a 1 -antitrypsin, asialoglycoprotein receptor, cytokeratin 8 (CK8), cytokeratin 18 (CK18), CYP3A4, fumaryl acetoacetate hydrolase (FAH), glucose-6-phosphates, tyrosine aminotransferase, phosphoenol- pyruvate carboxykinase, and tryptophan 2,3-dioxygenase. Selection or enrichment of cells of hepatocyte phenotype may further include a step of determining whether the cell of interest expresses a hepatocyte reporter gene or one or more hepatocyte characteristics as described herein.
[0081] Characteristics of the cells of hepatocyte phenotype provided in certain aspects of the invention include, but are not limited to one or more of the expression of one or more hepatocyte markers, the activity of liver-specific enzymes, the production of by-products of liver specific reactions such as bile and urea or bile secretion, or xenobiotic detoxification, morphological features characteristic of hepatocytes or in vivo liver engraftment in an immunodeficient subject. Two illustrative examples of a liver-specific enzymes the activity of which may be determined, are glucose-6-phosphatase and CYP3A4. Hepatocyte markers that may be analysed include, but are not limited to, HNF-3 , HNF-4a, cytochrome p450 3 A4 (CYP3A4), Bile Salt Export Pump (BSEP) glucose-6-phosphatase (G6PC), fructose- 1,6- bisphosphatase (FBP1), glycogen synthase 2 (GYS2), farnesoid X receptor (FXR), arginase Type 1 (ARG1), albumin such as human serum albumin (ALB) or a combination thereof. Further illustrative examples of suitable markers are a 1 -antitrypsin (AAT), cytokeratin 8 (CK8), cytokeratin 18 (CK18), asialoglycoprotein receptor (ASGR), alcohol dehydrogenase 1 and liver-specific organic anion transporter (LST-1). Fig. 2 illustrates the analysis of the expression of the hepatocyte markers HNF-Ια, HNF-3 , HNF-4a, HNF6, CYP3A4, BSEP, G6PC, FBP1, GYS2, FXR, ARG1, and ALB by way of RT-PCR with subsequent agarose gel electrophoresis. HNF6 expression could not be detected in samples where this transcription factor had not been heterologously introduced into the cell. The canalicular transporter BSEP was expressed in all cells following differentiation. G6PC showed weak expression in all cell samples. FBP1, a further gene encoding an enzyme of gluconeogenesis, was strongly expressed in differentiated cells transduced with HNF6. Likewise, expression of ARGl could only be detected in cells transduced with FINF6 following differentiation.
[0082] In a method of testing a compound for its hepatic effect one or more cells of hepatocyte phenotype obtained as described above are brought in contact with the compound of interest. A respective method may include adding the respective compound, typically a predetermined quantity thereof, to the cells of hepatocyte phenotype. In a typical embodiment the compound of interest is dissolved in a fluid, typically a liquid, which is then being added to the medium that encompasses the cells of hepatocyte phenotype.
[0083] In some embodiments a method according to the present invention includes contacting a cell of hepatocyte phenotype with a predetermined quantity of a compound of interest. In some embodiments at least two different predetermined quantities of a compound of interest are used. In some of these embodiments at least a first and a second cell of hepatocyte phenotype are used. The first cell is contacted with the lower of the two predetermined quantities and the second cell is contacted with the higher of the two predetermined quantities. Respective embodiments may for example be a screening assay, a cytotoxity test or the determination of a dose/response curve.
[0084] Any desired matter may be tested for its effect on hepatic cells based on the use of cells obtained as described above. In some embodiments the matter may include or be a low molecular weight compound, such as a pharmaceutically active compound. In some embodiments the matter may be a nutrient, a saccharide, an oligosaccharide, a polysaccharide, a vitamin, a nucleotide, an oligonucleotide, a polynucleotide or a combination of any of these examples. The matter may be tested may be any sample, such as, but not limited to, a soil sample, an air sample, an environmental sample, a cell culture sample, a bone marrow sample, a rainfall sample, a fallout sample, a sewage sample, a ground water sample, an abrasion sample, an archaeological sample, a food sample, an infection sample, a nosocomial infection sample, a production sample, a drug preparation sample, a biological molecule production sample, a protein preparation sample, a lipid preparation sample, a carbohydrate preparation sample, a space sample, an extraterrestrial sample or any combination thereof. The sample may furthermore have been prepared in form of a fluid, such as a solution. Examples include, but are not limited to, a solution or a slurry of a nucleotide, a polynucleotide, a nucleic acid, a peptide, a polypeptide, an amino acid, a protein, a synthetic polymer, a biochemical composition, an organic chemical composition, an inorganic chemical composition, a metal, a lipid, a carbohydrate, a combinatory chemistry product, a drug candidate molecule, a drug molecule, a drug metabolite or of any combinations thereof. Further examples include, but are not limited to, a suspension of a metal, a suspension of metal alloy, and a solution of a metal ion or any combination thereof, as well as a suspension of a cell, a virus, a microorganism, a pathogen, a radioactive compound or of any combinations thereof. It is understood that a sample may furthermore include any combination of the aforementioned examples.
[0085] For some embodiments of a method of testing matter for its effect on hepatic cells, compounds may be used in the form of a library. Examples of such libraries are collections of various small organic molecules, chemically synthesized as model compounds, or nucleic acid molecules containing a large number of sequence variants.
[0086] In embodiments where a plurality of candidate compounds are analysed for their hepatic effect according to a method of the present invention such an embodiment may typically called a screening process. These candidate compounds may be analysed independent from each other, e.g. concurrently, consecutively or in any way out of phase. The candidate compounds may for example be added to a cell culture medium. In some embodiments any number of steps of analysing a plurality of candidate compounds may for example be carried out automatically - also repeatedly, using for instance commercially available robots. For such purposes any number of automation devices may be employed, for instance an automated readout system, a pipetting robot, a rinsing robot, or a fully automated screening system. As an illustrative example, the process may be an in-vitro screening process, for example carried out in multiple-well microplates (e.g. conventional 48-, 96-, 384- or 1536 well plates) using one or more automated work stations. Hence, in some embodiments the invention provides a process of high-throughput screening. The method may also be carried out using a kit of parts, for instance designed for performing the present method.
[0087] In embodiments of a method of the invention where the effect of matter on the liver in an organism, e.g. a compound, of interest is tested, cells of hepatocyte phenotype of a corresponding species are provided according to the invention as described above. The cells of hepatocyte phenotype are contacted with the matter of interest. The cells are then incubated with the matter of interest, i.e. the contact of the cells with the matter is maintained. Testing the effect of matter on the liver, i.e. the hepatic effect, generally further includes assessing the viability and/or functionality of the cells of hepatocyte phenotype. In some embodiments the effect of matter may be monitored over a certain period of time, such as over a period from about 1 hour to about a week, e.g. 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 days or 6 days. The functionality of the cells of hepatocyte phenotype may be assessed by measuring any hepatocyte characteristic function, such as of the above illustrated functions.
[0088] The viability of the cells may be assessed by any suitable technique. In some embodiments microscopic analysis may be carried out, for example by determining the cellular morphology. Microscopic analysis may for example include determining the presence of signs selected from the group consisting of cellular stress, factor toxicity, cellular viability, and cellular death. The level of one or more metabolites indicative of cell viability may also be assessed in this regard. Two illustrative examples of a metabolite the intracellular level of which may be determined are urea or ammonia. Three illustrative examples of a protein the expression of which may be determined are liver albumin, beta galactosidase, and cytochrome P450.
[0089] In some embodiments of a method in accordance with the invention it is analysed whether apoptosis occurs, including is being initiated are progresses, in one or more cells of hepatocyte phenotype following contact with the compound of interest. Apoptosis is a programmed cell death and typically a mechanism in a multicellular organism to remove undesired cells. An apoptotic cell shows a characteristic morphology, by which it can be identified under a microscope. The occurrence and/or progress of apoptosis in a tumour cell may be monitored, for example by propodium iodide staining, Annexin V-FITC staining, flow cytometry analysis, or combinations thereof, as well as by determining mitochondrial dysfunction or caspase 3 activation.
[0090] Testing the hepatic effect may include contacting the cells of hepatocyte phenotype with one or more selected test compounds. In some embodiments such a method may further include determining whether metabolites of the test compounds or of other compounds, whether heterologously applied or homologously present.are formed. The formed metabolites, including the amount of formed metabolites and the pattern of metabolites generated, may then be compared to a reference experiment. A reference experiment may include cells that have not been contacted with the selected test compound(s) but have been contacted with test compound carrier substances. In some embodiments testing the hepatic effect includes determining the formation, in particular determining functional characteristics of the formation, of serum albumin, of fibrinogen, and at least one of the prothrombin group of clotting factors. Testing the hepatic effect may also include determining the formation and secretion, in particular determining functional characteristics of the formation and secretion of bile, lipoprotein, transferrin or complement proteins. Testing the hepatic effect may also include determining whether the cells synthesize, in particular determining functional characteristics of the synthesis of, glycoprotein or urea.As indicated above, testing the hepatic effect may include analysis of the metabolization of homologous and/or heterologous compounds.
[0091] The metabolization of homologous and/or heterologous compounds in hepatocyets and hepatocyte-like cells is carried out by so called drug-metabolizing enzymes, enzymes that catalyze the biotransformation of for instance drugs and xenobiotics. In some embodiments testing the hepatic effect may include determining test compound induction or inhibition of drug metabolizing phase I and phase II proteins or transporter and receptor proteins. In this regard drug-metabolizing enzymes can be classified into two main groups: oxidative or conjugative.
[0092] Phase I reactions, also termed nonsynthetic reactions, include, but are not limited to, oxidation, reduction, hydrolysis, cyclization and decyclization, addition of oxygen or removal of hydrogen. The reactions are carried out by mixed function oxidases. A typical reaction in a Phase I oxidation involves conversion of a C-H bond to a C-OH. A well known example of an oxidative group of enzymes that mediate phase I reactions are the NADPH- cytochrome P450 reductase (P450R)/cytochrome P450 (P450) electron transfer systems. Conjugation reactions are known as phase II reactions and are usually detoxicating in nature, typically involving the interactions of the polar functional groups of phase I metabolites. Conjugation may for instance occur with glucuronic acid, a sulfonate, glutathione, acetate or an amino acid. A well known example of an oxidative group of conjugative enzymes that mediate phase II reactions are the UDP-glucuronosyltransferases.
[0093] In some embodiments testing the hepatic effect of a compound of interest includes analysing whether phase I and/or phase II proteins of the cell can be induced or inhibited. Such induction or reduction of activity and or amount of enzymes in hepatocytes is well known in the art. As an illustrative example, the expression of CYP1 genes can be induced via the aryl hydrocarbon receptor (AhR) which dimerizes with the AhR nuclear trans locator, in response to many poly cyclic aromatic hydrocarbon (PAHs). Xenobiotics such as phenobarbital-like compounds (CAR), dexamethasone and rifampin-type of compounds (PXR) are known to cause the steroid family of orphan receptors, the constitutive androstane receptor (CAR) and pregnane X receptors (PXR) to heterodimerize with the retinoid X receptor (RXR) and transcriptionally activate the promoters of CYP2B and CYP3A gene expression. For the phase II drug-metabolizing enzymes, known phase II gene inducers include, but are not limited to, butylated hydroxyanisol (BHA), tertbutylhydroquinone (tBHQ), green tea polyphenol (GTP), (-)-epicatechin-3-gallate (EGCG) and the isothiocyanates (PEITC, sulforaphane). These compounds can activate the mitogen-activated protein kinase (MAPK) pathway via electrophilic-mediated stress response, resulting in the activation of bZIP transcription factor Nrf2 which dimerizes with Mafs and binds to the antioxidant / electrophile response element (ARE / EpRE) enhancers that are found in many phase II drug- metabolizing enzymes as well as many cellular defensive enzymes such as thioredoxins, GCS and HO-1, with the subsequent induction of gene expression of these genes.
[0094] In some embodiments of a method of the invention, for example where candidate compounds are analysed for their hepatic effect, cells of hepatocyte phenotype are cultured in co-culture with at least one of endothelial cells, Kupffer cells, hepatic stellate cells, cholangiocytes and fibroblasts.
[0095] The invention also provides a method of identifying a hepatic pathogen. The term "hepatic pathogen" as used herein refers to any pathogen, such as a bacterial, viral or parasitic pathogen, that is capable of infecting cells of the liver, in particular hepatocytes.
[0096] The invention also provides a method of treating a subject in need of an increase in liver function. The method includes administering to the subject cells of hepatocyte phenotype obtained as described above. Thereby liver function is increased. In such embodiments cells may be grown two-dimensionally, e.g. in a monolayer, or three- dimensionally, for example in the extracellular matrix.
[0097] Cells of hepatocyte phenotype obtained as described above may also be used for applications in spheroid and/or organoid cultures and synthetic scaffolds or bioartificial liver devices. The cells of hepatocyte phenotype may be used for therapeutic applications of at least one of viral or toxin mediated hepatitis, heredity diseases such as Wilson's disease, heamatochromatosis or alpha- 1 antitrypsin deficiency, and liver cirrhosis or liver cancer. In some embodiments, for such therapeutic applications the cells of hepatocyte phenotype are cultured in co-culture with endothelial cells, with Kupffer cells, hepatic stellate cells, cholangiocytes and/or fibroblasts (supra).
[0098] The listing or discussion of a previously published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the state of the art or is common general knowledge.
[0099] The invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms "comprising", "including," containing", etc. shall be read expansively and without limitation. Singular forms such as "a", "an" or "the" include plural references unless the context clearly indicates otherwise. Unless otherwise indicated, the term "at least" preceding a series of elements is to be understood to refer to every element in the series. The terms "at least one" and "at least one of include for example, one, two, three, four, or five or more elements. Slight variations above and below the stated ranges can be used to achieve substantially the same results as values within the ranges. Also, unless indicated otherwise, the disclosure of the ranges is intended as a continuous range including every value between the minimum and maximum values.
[0100] Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by exemplary embodiments and optional features, modification and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.
[0101] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.
[0102] Other embodiments are within the appending claims. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.
[0103] In order that the invention may be readily understood and put into practical effect, the invention is further illustrated by the following non limiting examples and the appended figures. As one of ordinary skill in the art will readily appreciate from the disclosure of the present invention, other compositions of matter, means, uses, methods, or steps, presently existing or later to be developed that perform substantially the same function or achieve substantially the same result as the corresponding exemplary embodiments described herein may likewise be utilized according to the present invention.
Culture of primary Hepatocytes
[0104] Primary hepatocytes were obtained from PRIMACYT Cell Culture Technology (Schwerin, Germany). After receipt the culture media was replaced by HCM medium and cells incubated at 5 % C02 and 37 °C. The media was replaced every 24 hours. Supernatant samples of media were collected and stored at -80 °C. Cytochrome p 450 3A4 activity was determined after maximally 4 days of culture.
Generation and expansion of USSC
[0105] Cord blood not suitable for clinical banking was, from a plurality of donors, applied for stromal stem cell generation in accordance with informed donor consent. Isolation of mononuclear cells (MNC), selective culture of MNC for USSC-generation and USSC- expansion were performed as described previously [Kogler, G., et al, J Exp Med (2004) 200, 2, 123-135].
[0106] The identity of stem cells from cord blood was ensured on the basis of the immunophenotype. The multipotent character of USSC was verified by using the absence of the markers OCT4a, NANOG and SOX2.
Molecular cloning and lentiviral transduction of USSC
[0107] Sequences coding for human hepatocytes nuclear factor la (FINFla), forkhead box A2 (FOXA2), hepatocytes nuclear factor 4a (FINF4a) and hepatocytes nuclear factor 6 (FINF6) were generated by PCR amplification of hepatocyte cDNA. Primers containing specific restriction sites were used to allow cloning of cDNA into the multiple cloning site of pUC2CL6IN-plasmid. Each forward-primer contained a kozak consensus sequence (GCCACC). HNFla and HNF4a cDNAs were inserted into ECORI and BAMHI restriction sites of pUC2CL6IN (Primer 5 '- 3 ' : HNF 1 a-forward: AAAGAATTCGCCACC ATGGTTTCTAAAC TGAGCCAG (SEQ ID NO: 31), HNF la-reverse: TTTGGATCCGGTTACTGGGAGGA AGAGG (SEQ ID NO: 32); FOXA2-forward: AAAGCTAGCGCCACCATGCTGGGAG CGGTGAAG (SEQ ID NO: 33), FOXA2-reverse: AAAGG ATCCTTTCTTCTCCCTTGCGT CTC (SEQ ID NO: 34); HNF4 a- forward: AAAGAATTCGCCACCATGCGACTCTCCAAA ACCCT (SEQ ID NO: 35), HNF4a-reverse: TTTGGATCCCCCCAAGCCCCAGCGGCTTG (SEQ ID NO: 36); HNF6-forward: AAACTCGAGGCCACCATGAACGCGCAGCTGACC AT (SEQ ID NO: 37), HNF6-reverse: TTTGCTAGCGTGGTTCTTCCTTCATGCTT, SEQ ID NO: 38). FOXA2 was inserted into NHEI and BAMHI restriction sites of pUC2CL6IN. HNF6 was inserted into XHOI and BAMHI restriction sites of pUC2CL6IN. After construction, plasmids were combined with packaging plasmid pCD/NLBH and envelope plasmid pALF- GALV and integrated by FUGENE-transfection (Roche, Mannheim, Germany) into Hek293T cells for lentiviral production. After 24 hrs, supernatants containing lentiviruses were collected and passed through a 45 μιη syringe- filter (Fischer Scientific, Schwerte, Germany). Filtered and 1 :4 diluted supernatants were used for infection of 3.5A103 USSC per cm2. After 24 hrs, medium was changed and the cells were cultured in USSC expansion medium. To enrich transfected USSC, a neomycin-resistance cassette within pUC2CL6IN was used by addition of Geneticin sulfate (G418) (PAA, Colbe, Germany) into culture media. In order to determine transduction efficiencies, USSC were transduced with the vector pCL6IEGwo containing eGFP transgene controlled by a SFFV promoter. Transduction was accomplished as described above for constructed pUC2CL6IN-plasmids. The amounts of transduced cells were determined 5 days after lentiviral transduction by flow cytometric analysis.
Differentiation of transduced USSC
[0108] For hepatic differentiation of transduced USSC, 5Λ103 cells were plated per cm2 and cultured in expansion medium supplemented with 400 μg/ml G418. After reaching 70% confluence, cells were cultured in differentiation medium (WilliamsE Medium: 95%; FCS: 5%, 2 mM L-Glutamine; 50 U/ml Penicillin; 50 mg/ml Streptomycin, (Invitrogen, Karlsruhe, Germany); 4.5 μg/ml linoleic acid; 1 x ITS; 4.1 mM nicotinamid, (Sigma- Aldrich, Schnelldorf, Germany) 10 ng/ml EGF, 20 ng/ml HGF, and 1 μΜ retinoic acid for 5 days. Subsequently, cells were cultured in HDM with addition of 10 ng/ml EGF, 10 ng/ml HGF, 20 ng/ml OSM and 0.1 μΜ dexamethason for 7 days.
Flow cytometry analysis
[0109] Cell cultures expressing eGFP were dissociated using 0.25%> trypsin (Lonza, Cologne, Germany) for 5 min followed by addition of PBS containing 5% FCS. Resulting cell suspensions were pelleted and resuspended in PBS. Samples of 105 cells were analysed using a FACSCanto flow cytometer (BD Biosciences, Heidelberg, Germany) with FACS DIVA software. Analysis of eGFP expression (n=6) was performed in parallel to iH-USSC generation experiments with different USSC cell populations.
Immunofluorescence analysis [0110] For immunofluorescence analysis, cells were differentiated on Chamber Slides (Fischer Scientific, Schwerte, Germany), washed with PBS, fixed with 3.6% paraformaldehyde for 15 min at room temperature and permeabilized with methanol for 5 min at -20°C. After washing 3 times with PBS and blocking in blocking buffer (PBS: 94.97%; goat serum: 5%, (Dianova, Hamburg, Germany); TritonXlOO: 0.03%>, (Sigma-Aldrich, Schnelldorf, Germany)) for 60 min, slides were stained with primary antibodies diluted in dilution buffer (PBS: 99.97%; bovine serum albumin (BSA): 1% (Sigma-Aldrich, Schnelldorf, Germany); TritonXlOO: 0.03%) at 4 °C overnight. Antibodies applied were: mouse anti HNF4a (clone K9218, Perseus Proteomics, dilution 1 :200), mouse anti HNF6 (clone 4F12, Novus, dilution 1 :200), rabbit anti FOXA2 (#3143, Cell signalling, dilution 1 :800), rabbit anti HNFla (sc- 10791, Santa Cruz, dilution 1 :200).
[0111] The incubation with fluorescent dye-conjugated secondary antibodies diluted in antibody dilution buffer was performed for 60 min at room temperature. Before and after incubation, slides were washed three times with PBS. Nuclei were stained with DAPI contained in the ProLong® Gold antifade mounting-reagent (Invitrogen, Karlsruhe, Germany). All prepared slides were analyzed using Zeiss Axioplan2 microscope and Axiovision Software (Carl Zeiss Microimaging, Gottingen, Germany) with according filter (DAPI: 365 nm; FITC: 470 nm and Rhodamin 546 nm).
[0112] Determination of total cell numbers stained positive for a defined marker was performed by counting positively stained cells versus total cells represented by DAPI staining.
RNA isolation and reverse transcription polymerase chain reaction (RT-PCR)
[0113] RNA isolation from cell lines and cell populations was performed applying RNeasy Mini Kit with additional on-column DNase digestion (Qiagen, Hilden, Germany). Total human fetal liver RNA (MVP™ Total RNA, pooled from male donors, gestation weeks 18 - 20) was purchased from Stratagen (La Jo 11a, CA, USA). 0.5-1.0 μg of total RNA was reversely transcribed afterwards into cDNA using SuperScriptlll (Invitrogen, Karlsruhe, Germany), according to manufacturer's instructions. RT-PCR and real time PCR
[0114] Conventional RT-PCR was performed using 1 μΐ cDNA as template in 25 μΐ final reaction volume comprising l x PCR buffer containing 1.5 mM MgCl2, 0.2 μΜ of each primer, 0.2 mM of each dNTP and 1.25 U HotStar-Taq DNA Polymerase (Qiagen, Hilden, Germany) in a Mastercycler EP (Eppendorf, Hamburg, Germany). [0115] Quantitative real time PCR (qPCR) was carried out by setting up reactions in triplicates, containing SYBR® Green PCR Mastermix (Applied Biosystems, Darmstadt, Germany), 0.2 μΜ of each primer as well as 50 ng of reverse transcribed total RNA, and subsequent analysis on ABI prism 7700 real-time PCR system (Applied Biosystems, Darmstadt, Germany). All qPCR results refer to the (housekeeping) gene Glyceraldehyde-3- phosphate dehydrogenase (GAPDH). Analyses correspond to a minimum of 3 independently isolated RNA samples per time point of differentiation. Primer sequences are listed in Fig. 11.
Detection of human albumin, urea and cytochrome-p450-3A4 activity
[0116] Supernatants of differentiated cells, HepG2 cells and primary hepatocytes were collected after an incubation time for 24 hrs and stored at -80°C. Concentration of human albumin was assessed by ELISA (Bethyl Labs, Montgomery, USA) and concentration of urea was measured by the QuantiChrom™ Urea assay (BioAssay Systems, Hayward, USA). Both assays were carried out in accordance with manufacturer's instructions and analyzed in a microplate reader 680 (Biorad, Munchen, Germany). HDM supplemented with growth factors was used as negative control.
[0117] The detection of CYP3A4 activity was performed applying the P450-Glo™ CYP3A4- Assay (Promega, Mannheim, Germany). Inducible CYP3A4 activity was determined by culturing differentiated cells with or without 25 μΜ rifampicin (Sigma-Aldrich, Schnelldorf, Germany) for 48 hrs before testing. Prior to testing, cells were washed twice with PBS and incubated in HDM containing luciferin-PFBE substrate (50 μΜ) for 3-4 hrs. Subsequently, 50 μΐ of supernatant were mixed in equal parts with luciferin detection reagent, incubated for 20 min and measured with a tube-luminometer (Berthold Analytical, Nashua, USA).
[0118] Hepatocyte functions of transduced USSC were analyzed by determining the amount of human albumin and urea in cell culture supernatants or by evaluating CYP3A4 substrate metabolization by transduced USSC. Albumin secretion, urea production and inducible cytochrome-p450-3A4 activity as performed by transduced USSC demonstrated functional activity of transduced USSC in a hepatocyte specific manner. This designates the cells of hepatocyte phenotype described herein as suitable alternatives for hepatocyte based applications.
Statistical analysis [0119] Statistical data analyses were performed applying PRISM 2.01 (GraphPad Software, Inc., La Jolla, USA). Data were compared by means of student's two sided t-test, and a -value lower than 0.05 was considered significant.
[0120] Imunocytochemical staining showed that all neonatal stem cell populations used expressed DLK-1, thus falling under the definition of USSC. In these examples USSC have been exposed to a short differentiation culture in order to facilitate assessment of differences between transcription factor induced USSC and Mock controls.
[0121] Overexpression was carried out using the vector pUC2CL6IN (pUCC2) and constructs were analysed using PCR, restriction analysis, and subsequent sequencing. This vector contains a neomycin resistance, which allowed enriching transduced cells in culture by selection via geneticin sulphate. As a control, USSC transduced with an empty vector were subjected to a toxicity test. Transduction efficiency was assessed in parallel experiments, where USSC were transduced with a corresponding vector pCL6IEGwo (pCL6) that encodes the enhanced green fluorescent protein. Transduced factors were found to be located in the nucleus in essentially all cells. Overexpression of HNFla and FINF6, respectively, in USSC lead to an increase in gene expression of a few markers following differentiation. In transduced USSC after differentiation high expression of CYP3A4 was found. FXR expression is selectively and strongly initiated. These observations are in line with previous reports in the art on a positive regulation of the FXR promotor in HepG2 cells. After differentiation FINF6 transduced USSC expressed FBP1, GYS2 and ARG1 in high amounts (cf. Fig. 2).

Claims

Claims What is claimed is:
1. An in vitro method of generating cells of hepatocyte phenotype, the method comprising increasing in adherent adult multipotent cells the amount of the transcription factor hepatocyte nuclear factor 6 (HNF-6) and the amount of the transcription factor hepatocyte nuclear factor la (FiNF-la).
2. The method of claim 1, further comprising increasing in the adherent adult multipotent cells the amount of the transcription factor hepatocyte nuclear factor 4a (FiNF-4a).
3. The method of claim 1 or claim 2, further comprising increasing in the adherent adult multipotent cells the amount of the transcription factor hepatocyte nuclear factor 3β (HNF-3 ).
4. The method of any one of claims 1-3, wherein the adherent adult multipotent cells are cord blood stem cells.
5. The method of any one of claims 1 - 4, wherein the adherent adult multipotent cells are mesenchymal stem cells (MSC) or unrestricted somatic stem cells (USSC).
6. The method of any one of claims 1-5, wherein increasing in adherent adult multipotent cells the amount of at least one of the respective transcription factors comprises increasing gene expression of the transcription factor.
7. The method of claim 6, wherein increasing gene expression of the transcription factor comprises expressing a heterologous nucleic acid sequence encoding the transcription factor.
8. The method of claim 7, wherein the heterologous nucleic acid sequence is comprised in a vector.
9. The method of claim 8, wherein the vector is a lentivirus vector.
10. The method of any one of claims 1-9, further comprising: culturing the cells in co-culture with at least one of endothelial cells, Kupffer cells, hepatic stellate cells, cholangiocytes, and fibroblasts, after increasing the amounts of HNF-6 and HNF-la.
11. The method of any one of claims 1-10, further comprising: after increasing the amounts of FiNF-6 and FiNF-la, culturing the cells in spheroid and/or organoid culture.
12. The method of any one of claims 1-11, further comprising: after increasing the amounts of FiNF-6 and FiNF-la, forming a synthetic scaffold or a bioartificial liver device with the cells.
13. The use of cells of hepatic phenotype obtained by the method according to any one of claims 1-11 for testing the hepatic effect of a compound of interest, wherein testing the hepatic effect comprises contacting the cells of hepatic phenotype with the compound of interest.
14. The use of claim 13, wherein testing the hepatic effect comprises at least one of determining the occurrence of apoptosis and determining cell viability of the cells of hepatic phenotype.
15. The use of claims 13 or 14, wherein testing the hepatic effect comprises determining the cells' activity in (i) generating at least one of serum albumin, fibrinogen, a clotting factor of the prothrombin group, bile, lipoprotein, transferrin, complement protein and glycoprotein, and urea and/or in (ii) metabolizing homologous and/or a heterologous compound.
16. The use of claim 15, wherein determining the cells's activity in metabolizing heterologous compounds comprises determining the formation of metabolites of the heterologous compound.
17. The use of any one of claims 13-16, wherein testing the hepatic effect comprises determining whether drug metabolizing phase I and phase II proteins or transporter and receptor proteins of the cell can be induced or inhibited. The use of cells of hepatic phenotype obtained by the method according to any one of claims 1-12 for therapeutic applications of at least one of hepatitis, a heredity disease, liver cirrhosis and liver cancer.
The use of claim 18, wherein the heredity disease is one of Wilson's disease, heamatochromatosis and alpha- 1 antitrypsin deficiency.
PCT/EP2012/061679 2012-06-19 2012-06-19 Method of generating cells of hepatocyte phenotype WO2013189521A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/061679 WO2013189521A1 (en) 2012-06-19 2012-06-19 Method of generating cells of hepatocyte phenotype
PCT/EP2013/062805 WO2013190013A1 (en) 2012-06-19 2013-06-19 Cell of hepatocyte phenotype

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/061679 WO2013189521A1 (en) 2012-06-19 2012-06-19 Method of generating cells of hepatocyte phenotype

Publications (1)

Publication Number Publication Date
WO2013189521A1 true WO2013189521A1 (en) 2013-12-27

Family

ID=48803502

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2012/061679 WO2013189521A1 (en) 2012-06-19 2012-06-19 Method of generating cells of hepatocyte phenotype
PCT/EP2013/062805 WO2013190013A1 (en) 2012-06-19 2013-06-19 Cell of hepatocyte phenotype

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/062805 WO2013190013A1 (en) 2012-06-19 2013-06-19 Cell of hepatocyte phenotype

Country Status (1)

Country Link
WO (2) WO2013189521A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086132A1 (en) * 2014-11-26 2016-06-02 Accelerated Biosciences Corp. Induced hepatocytes and uses thereof
US9574173B2 (en) 2010-11-15 2017-02-21 Accelerated Biosciences Corp. Generation of neural stem cells from human trophoblast stem cells
CN107034170A (en) * 2017-01-11 2017-08-11 暨南大学 Culture medium and method that fat mesenchymal stem cell breaks up simultaneously to HSCs and liver endothelial cell
EP3702449A4 (en) * 2017-10-23 2021-07-28 Kyushu University, National University Corporation Method for producing liver stem cells or liver progenitor cells by direct reprogramming

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11426370B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11590124B2 (en) 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9457025B2 (en) 2013-11-05 2016-10-04 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US11426401B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10688066B2 (en) 2018-03-20 2020-06-23 Antecip Bioventures Ii Llc Bupropion and dextromethorphan for treating nicotine addiction
US10874665B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9968568B2 (en) 2013-11-05 2018-05-15 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10080727B2 (en) 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US20200338022A1 (en) 2019-01-07 2020-10-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11439636B1 (en) 2013-11-05 2022-09-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9474731B1 (en) 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11497721B2 (en) 2013-11-05 2022-11-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291638B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11065248B2 (en) 2013-11-05 2021-07-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11191739B2 (en) 2013-11-05 2021-12-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11197839B2 (en) 2013-11-05 2021-12-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9707191B2 (en) 2013-11-05 2017-07-18 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11576909B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576877B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as modulator of drug activity
US10945973B2 (en) 2013-11-05 2021-03-16 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285118B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10874664B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11344544B2 (en) 2013-11-05 2022-05-31 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9763932B2 (en) 2013-11-05 2017-09-19 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11234946B2 (en) 2013-11-05 2022-02-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11058648B2 (en) 2013-11-05 2021-07-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11364233B2 (en) 2013-11-05 2022-06-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10813924B2 (en) 2018-03-20 2020-10-27 Antecip Bioventures Ii Llc Bupropion and dextromethorphan for treating nicotine addiction
US10980800B2 (en) 2013-11-05 2021-04-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10894046B2 (en) 2013-11-05 2021-01-19 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571399B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10864209B2 (en) 2013-11-05 2020-12-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11096937B2 (en) 2013-11-05 2021-08-24 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10940124B2 (en) 2019-01-07 2021-03-09 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20220233470A1 (en) 2013-11-05 2022-07-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966974B2 (en) 2013-11-05 2021-04-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20160324807A1 (en) 2013-11-05 2016-11-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10512643B2 (en) 2013-11-05 2019-12-24 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US20200261431A1 (en) 2019-01-07 2020-08-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11510918B2 (en) 2013-11-05 2022-11-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11007189B2 (en) 2013-11-05 2021-05-18 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11273133B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9457023B1 (en) 2013-11-05 2016-10-04 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10105327B2 (en) 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
US11357744B2 (en) 2013-11-05 2022-06-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10894047B2 (en) 2013-11-05 2021-01-19 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11596627B2 (en) 2013-11-05 2023-03-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291665B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571417B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11517543B2 (en) 2013-11-05 2022-12-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11090300B2 (en) 2013-11-05 2021-08-17 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617747B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11311534B2 (en) 2013-11-05 2022-04-26 Antecip Bio Ventures Ii Llc Bupropion as a modulator of drug activity
US11298352B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10933034B2 (en) 2013-11-05 2021-03-02 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10772850B2 (en) 2013-11-05 2020-09-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10799497B2 (en) 2013-11-05 2020-10-13 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US9402843B2 (en) 2013-11-05 2016-08-02 Antecip Bioventures Ii Llc Compositions and methods of using threohydroxybupropion for therapeutic purposes
US11285146B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966941B2 (en) 2013-11-05 2021-04-06 Antecip Bioventures Ii Llp Bupropion as a modulator of drug activity
US11382874B2 (en) 2013-11-05 2022-07-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11253491B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298351B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11229640B2 (en) 2013-11-05 2022-01-25 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11141416B2 (en) 2013-11-05 2021-10-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9700528B2 (en) 2013-11-05 2017-07-11 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9861595B2 (en) 2013-11-05 2018-01-09 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US20160361305A1 (en) 2013-11-05 2016-12-15 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US11478468B2 (en) 2013-11-05 2022-10-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11020389B2 (en) 2013-11-05 2021-06-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541021B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10898453B2 (en) 2013-11-05 2021-01-26 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10874663B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617728B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11185515B2 (en) 2013-11-05 2021-11-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10786469B2 (en) 2013-11-05 2020-09-29 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9867819B2 (en) 2013-11-05 2018-01-16 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11213521B2 (en) 2013-11-05 2022-01-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123343B2 (en) 2013-11-05 2021-09-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11273134B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10881657B2 (en) 2013-11-05 2021-01-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11147808B2 (en) 2013-11-05 2021-10-19 Antecip Bioventures Ii Llc Method of decreasing the fluctuation index of dextromethorphan
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11524007B2 (en) 2013-11-05 2022-12-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966942B2 (en) 2019-01-07 2021-04-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11207281B2 (en) 2013-11-05 2021-12-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11253492B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123344B2 (en) 2013-11-05 2021-09-21 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US11129826B2 (en) 2013-11-05 2021-09-28 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US11541048B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11419867B2 (en) 2013-11-05 2022-08-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10105361B2 (en) 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
CA3001341C (en) 2015-10-15 2024-05-14 Wake Forest University Health Sciences Methods of producing in vitro liver constructs and uses thereof
WO2017139455A1 (en) * 2016-02-10 2017-08-17 Wake Forest University Health Sciences Model system of liver fibrosis and method of making and using the same
US10925842B2 (en) 2019-01-07 2021-02-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
JP2023516484A (en) 2020-03-11 2023-04-19 ビット バイオ リミテッド Hepatocyte production method
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
WO2001004144A2 (en) 1999-07-13 2001-01-18 Scil Proteins Gmbh Fabrication of beta-pleated sheet proteins with specific binding properties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2005019254A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US20050191618A1 (en) 2001-05-18 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
WO2008002662A2 (en) * 2006-06-28 2008-01-03 The Univeristy Of Kansas Differentiation of stem cells from umbilical cord matrix into hepatocyte lineage cells
WO2008035169A2 (en) * 2006-09-18 2008-03-27 Universita' Degli Studi Di Torino Process for preparing hepatic cells from progenitor cells present in umbilical cord blood
US20090317365A1 (en) * 2008-06-23 2009-12-24 Lee Oscar Kuang-Sheng Systems and methods for making hepatocytes from extrahepatic somatic stem cells and use thereof
WO2010014949A2 (en) * 2008-07-31 2010-02-04 The General Hospital Corporation Compositions comprising hepatocyte-like cells and uses thereof
WO2011130402A2 (en) * 2010-04-13 2011-10-20 Cellular Dynamics International, Inc. Hepatocyte production by forward programming

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
WO2001004144A2 (en) 1999-07-13 2001-01-18 Scil Proteins Gmbh Fabrication of beta-pleated sheet proteins with specific binding properties
US20050191618A1 (en) 2001-05-18 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2005019254A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
WO2005019256A2 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
WO2008002662A2 (en) * 2006-06-28 2008-01-03 The Univeristy Of Kansas Differentiation of stem cells from umbilical cord matrix into hepatocyte lineage cells
WO2008035169A2 (en) * 2006-09-18 2008-03-27 Universita' Degli Studi Di Torino Process for preparing hepatic cells from progenitor cells present in umbilical cord blood
US20090317365A1 (en) * 2008-06-23 2009-12-24 Lee Oscar Kuang-Sheng Systems and methods for making hepatocytes from extrahepatic somatic stem cells and use thereof
WO2010014949A2 (en) * 2008-07-31 2010-02-04 The General Hospital Corporation Compositions comprising hepatocyte-like cells and uses thereof
WO2011130402A2 (en) * 2010-04-13 2011-10-20 Cellular Dynamics International, Inc. Hepatocyte production by forward programming

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
BESTE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 1898 - 1903
GILL, D.S.; DAMLE, N.K., CURRENT OPINION IN BIOTECHNOLOGY, vol. 17, 2006, pages 653 - 658
HOLT, L.J. ET AL., TRENDS BIOTECHNOL., vol. 21, no. 11, 2003, pages 484 - 490
HONG S H ET AL: "In vitro differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocyte-like cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 330, no. 4, 20 May 2005 (2005-05-20), pages 1153 - 1161, XP004844850, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2005.03.086 *
ILIADES, P. ET AL., FEBS LETT, vol. 409, 1997, pages 437 - 441
KASHOFER, K ET AL., STEM CELLS, vol. 24, 2006, pages 1104 - 1112
KOGLER, G. ET AL., J EXP MED, vol. 200, no. 2, 2004, pages 123 - 135
KRIITZFELDT, J. ET AL., NATURE, vol. 438, no. 2005, pages 685 - 689
KWON, Y.-U.; KODADEK, T., J. AM. CHEM. SOC., vol. 129, 2007, pages 1508 - 1509
LIU, B. ET AL., J. AM. CHEM. SOC., vol. 126, 2004, pages 4076 - 4077
MORRISSEY ET AL., NATURE BIOTECH., vol. 23, no. 8, 2005, pages 1002 - 1007
MOSAVI, L.K. ET AL., PROTEIN SCIENCE, vol. 13, no. 6, 2004, pages 1435 - 1448
PATZEL, V. ET AL., NATURE BIOTECH., vol. 23, 2005, pages 1440 - 1444
SILVERMAN, J ET AL., NATURE BIOTECHNOLOGY, vol. 23, 2005, pages 1556 - 1561
SIMION, A ET AL., BIOCHEM BIOPHYS RES COMMUN., vol. 391, no. 1, 2010, pages 293 - 298
SKERRA, J. MOL. RECOGNIT., vol. 13, 2000, pages 167 - 187
SMITH ET AL., J. MOL. BIOL., vol. 147, 1981, pages 195 - 197
SONG, E. ET AL., NATURE BIOTECH., vol. 23, no. 6, 2005, pages 709 - 717
STONE, E. ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 318, 2007, pages 88 - 94
VASSILOPOULOS, G ET AL., NATURE, vol. 422, 2003, pages 901 - 904
WEISSLEDER ET AL., NATURE BIOTECH., vol. 23, no. 11, 2005, pages 1418 - 1423
XIANG ET AL., NATURE BIOTECH., vol. 24, no. 6, 2006, pages 697 - 702
YAMADA T ET AL: "In vitro differentiation of embryonic stem cells into hepatocyte-like cells identified by cellular uptake of indocyanine green", STEM CELLS, ALPHAMED PRESS, DAYTON, OH, US, vol. 20, no. 2, 1 January 2002 (2002-01-01), pages 146 - 154, XP002321740, ISSN: 1066-5099, DOI: 10.1634/STEMCELLS.20-2-146 *
ZAMORE, PD; HALEY, B, SCIENCE, vol. 309, 2005, pages 1519 - 1524

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11254911B2 (en) 2010-11-15 2022-02-22 Accelerated Biosciences Corp. Generation of neural stem cells from human trophoblast stem cells
US9574173B2 (en) 2010-11-15 2017-02-21 Accelerated Biosciences Corp. Generation of neural stem cells from human trophoblast stem cells
US11891623B2 (en) 2010-11-15 2024-02-06 Accelerated Biosciences Corp. Generation of neural stem cells from human trophoblast stem cells
GB2548059B (en) * 2014-11-26 2020-09-02 Accelerated Biosciences Corp Induced hepatocytes and uses thereof
US9808490B2 (en) 2014-11-26 2017-11-07 Accelerated Biosciences Corp. Induced hepatocytes and uses thereof
EP3224347A4 (en) * 2014-11-26 2018-08-15 Accelerated BioSciences Corp. Induced hepatocytes and uses thereof
WO2016086132A1 (en) * 2014-11-26 2016-06-02 Accelerated Biosciences Corp. Induced hepatocytes and uses thereof
US10765704B2 (en) 2014-11-26 2020-09-08 Accelerated Biosciences Corp. Induced hepatocytes and uses thereof
US11026979B2 (en) 2014-11-26 2021-06-08 Accelerated Biosciences Corp. Human hepatocytes and uses thereof
AU2015353521B2 (en) * 2014-11-26 2021-11-04 Accelerated Biosciences Corp. Induced hepatocytes and uses thereof
GB2548059A (en) * 2014-11-26 2017-09-06 Accelerated Biosciences Corp Induced hepatocytes and uses thereof
CN107034170B (en) * 2017-01-11 2020-10-30 暨南大学 Culture medium and method for simultaneous differentiation of adipose-derived mesenchymal stem cells into hepatic stellate cells and hepatic endothelial cells
CN107034170A (en) * 2017-01-11 2017-08-11 暨南大学 Culture medium and method that fat mesenchymal stem cell breaks up simultaneously to HSCs and liver endothelial cell
EP3702449A4 (en) * 2017-10-23 2021-07-28 Kyushu University, National University Corporation Method for producing liver stem cells or liver progenitor cells by direct reprogramming
US11981927B2 (en) 2017-10-23 2024-05-14 Kyushu University, National University Corporation Method for producing liver stem cells or liver progenitor cells by direct reprogramming

Also Published As

Publication number Publication date
WO2013190013A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
WO2013189521A1 (en) Method of generating cells of hepatocyte phenotype
Kamiya et al. Role of the hepatocyte nuclear factor 4α in control of the pregnane X receptor during fetal liver development
Apáti et al. High level functional expression of the ABCG2 multidrug transporter in undifferentiated human embryonic stem cells
Lavon et al. The effect of overexpression of Pdx1 and Foxa2 on the differentiation of human embryonic stem cells into pancreatic cells
KR20150052228A (en) Methods and compositions for producing induced hepatocytes
EP2666857B1 (en) Nucleic acid construct for expressing oxidative stress indicator and use thereof
Gomez-Ospina et al. A promoter in the coding region of the calcium channel gene CACNA1C generates the transcription factor CCAT
US9102920B2 (en) Method of effecting de-differentiation of a cell
Liew et al. PAX4 enhances beta-cell differentiation of human embryonic stem cells
Fossat et al. Context-specific function of the LIM homeobox 1 transcription factor in head formation of the mouse embryo
Onodera et al. Conserved structure, regulatory elements, and transcriptional regulation from the GATA-1 gene testis promoter
US20140287944A1 (en) Markers for functionally mature beta-cells and methods of using the same
Nueda et al. The novel gene EGFL9/Dlk2, highly homologous to Dlk1, functions as a modulator of adipogenesis
Chung et al. Ascorbate promotes epigenetic activation of CD30 in human embryonic stem cells
US20150219627A1 (en) Compendium of ready-built stem cell models for interrogation of biological response
Sapetto-Rebow et al. Maternal topoisomerase II alpha, not topoisomerase II beta, enables embryonic development of zebrafish top2a-/-mutants
Siehler et al. Generation of a heterozygous C-peptide-mCherry reporter human iPSC line (HMGUi001-A-8)
WO2018014005A1 (en) Multiple-reporter systems for indirectly screening differentiated cells by cell type and/or cell function
CN112921053A (en) Dual-induction mCreER system capable of tracking cell differentiation and development and establishment and application thereof
CN116802272A (en) Fluorescent protein-labeled cytochrome P450 transformed human induced pluripotent stem cell line and screening method for AHR modulator using same
EP3123169A1 (en) Flattop (fltp) is a novel biomarker for beta cell maturation
US20230374451A1 (en) Immortalized keratinocytes, lentivirus for keratinocyte immortalization, and methods of use
US11981930B2 (en) Supercentenarian induced pluripotent stem (sciPS) cells and methods of making and using thereof
JP4374454B2 (en) F9 embryonic tumor cells that can be used for protein production and use thereof
Wallenstein et al. Transient gene delivery for functional enrichment of differentiating embryonic stem cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12737227

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12737227

Country of ref document: EP

Kind code of ref document: A1